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I Overview
The 2014 Work Programme continues to implement the 
commitments set out in the EMCDDA’s 2013–15 strategy and 
work programme. It builds on the achievements made in 2013 
where measures were put in place to ensure that the EMCDDA’s 
approach remains appropriate to the challenge of reporting on 
an evolving drug situation within the context of changing 
customer needs and expectations. Work for 2014 is 
underpinned by the core principles of the strategy which are to 
ensure: the relevance and timeliness of our reporting; that our 
working practices are efficient and maximise investments made; 
and that we remain communication and customer focused.
In 2014, work on a number of overarching areas will be taken 
forward. The new communication approach introduced in 
2013 gives greater focus to integrated online information 
products. In the first phase, the European Drug Report 
package replaced the old Annual report format. In 2014, we 
will move to the second phase and overhaul our web content, 
beginning with the task of rationalising our reporting of 
national level data and continuing to concentrate on 
timeliness. In the context of diminishing resources, we give 
high priority to ensuring that the agency’s reporting tools and 
processes remain efficient and fit for purpose. This is reflected 
in the introduction of new quality assurance procedures and 
more efficient working practices, as well as the scaling down 
of activities in some areas.
The financial resources required for implementing the 2014 
Work Programme will be provided by the EMCDDA budget for 
2014, as adopted by its Management Board. The budget 
becomes definitive after final adoption of the general budget 
of the European Union setting the amount of the subsidy. The 
2014 draft EU budget envisages the amount of EUR 14 
794 000 for the EMCDDA. This represents a reduction in the 
EU funding of almost 5 % compared to 2013. This work 
programme has been drawn up on the basis of this 
assumption. Changes in the amount of the subsidy would lead 
to further adjustments to the activities proposed here.
I Prioritising work in 2014
While our vision remains set on further increasing the value of 
the agency’s work to better support Europe in responding to 
its drug problems, our 2014 activities are framed within the 
context of the realities we face today which include a stable/
diminishing reporting capacity at Member State level and 
reduced human and financial resources at our disposal. It has 
therefore proved necessary to review and remove, or 
downscale or postpone, some of the achievements envisaged 
in the three-year strategy (a list of the key outputs concerned 
is provided in the section ‘Key outputs to be published in 2014 
and their intended audience’). Moreover, to safeguard 
EMCDDA core tasks, and to allow the agency to respond 
appropriately to the impact of resource deficits as they 
become apparent, all activities listed here have been subject 
to a prioritisation exercise. When doing this we have focused 
on ensuring the agency’s core obligations and efficient 
working practices. It has also been necessary to internalise 
scientific tasks as far as possible to ensure the budget for 
external studies is as low as possible. The budget line for 
studies available for scientific work is envisaged at around half 
the size of the 2012 allocation and this will be used to provide 
additional expertise in critical areas, which is essential for our 
work. The budget perspective also has an impact on human 
resources and has already resulted in the loss of expertise 
that is difficult to compensate in the short term and therefore 
some external input is necessary to assure core tasks. Difficult 
choices still have to be made and among these is a potential 
reduction of the financial support provided to support national 
data collection and reporting efforts. A reduction in this area, 
combined with the current pressures on national budgets 
across Europe, is likely to impact on national data collection 
and therefore have a knock-on effect on reporting to the 
EMCDDA. This has been anticipated in the 2014 Work 
Programme as far as is possible. The reporting burden placed 
on national focal points will be reviewed and the EMCDDA will 
continue to work on rationalising it so as to ensure that the 
overall system is cost efficient. A holistic approach is needed 
here and one of the implications is that not all reporting areas 
can be awarded the same priority.
Given that some important decisions that will impact on 
internal budget allocation are still awaited, the activities 
outlined and prioritised here may require further review. Whilst 
all activities envisaged by this work programme can be 
regarded as necessary for the EMCDDA to fulfil its mandate, 
they can be differentiated with regard to the extent to which 
they are critically essential in order for the agency to 
accomplish its core tasks. This allows us to build some 
flexibility into the planning exercise. Indispensable tasks can 
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preparation of new analysis of HCV in Europe which explores 
both the scale of the problem and recent developments in 
treatment. To achieve more complex analysis, and to 
maximise the scientific capacities available within the 
EMCDDA, more flexible working practices are required within 
the scientific teams accompanied by a greater investment in 
transversal and joined-up working. This is supported by the 
introduction of the quality assurance framework, cross-unit 
projects (CUPs), a new planning approach to scientific 
meetings and a greater focus on shared outputs. 
Methodological and developmental activities are to a large 
extent restricted to ensuring that existing tools are 
appropriately configured to the contemporary drug problem. 
Examples of this include the launch of new problem drug use 
(PDU) guidelines, a review of the drug-related infectious 
diseases (DRID) indicator and pilot work to look at drug 
emergencies and non-opiate related mortality. The EMCDDA 
has to ensure that its reporting tools remain fit for purpose 
when measured against a more complex drug situation in 
which polydrug use patterns predominate. The agency will 
also release a publication on cannabis treatment (in its 
Insights series), reflecting the increased relative importance of 
cannabis within the overall European treatment picture.
Although the focus of this work programme is on analysis 
rather than methodological development, the area of supply 
reduction is an exception. Improving the quality of data in this 
area is one of the priorities of the three-year work programme 
and developmental activities are necessary. These activities 
include pilot work to improve the information available on the 
disruption of major cannabis cultivation and synthetic drug 
production sites. On the analytical side, supply and demand 
data will be used in exploratory work to provide a better 
estimate of the size of the European drug market. The 
demands on the EMCDDA in the area of new psychoactive 
substances continue to grow. The Early-warning system 
(EWS) is supported by an in-house database, the European 
database on new drugs (EDND), which lacks both the 
functionality and the capacity to meet current and future 
needs of the EWS. Improving the EDND is therefore a priority 
for 2014. The work programme also takes into account the 
need to reconfigure activities in support of EWS as a result of 
the Commission’s proposal for changes to the legal basis for 
this work. Increased activities are an expected result of the 
scaled up cooperation with the ESPAD (European school 
survey project on alcohol and other drugs) group, where the 
EMCDDA is supporting coordination tasks and joint analysis of 
data. The agency will also continue the review of its 
responsibilities with regard to the new EU action plan on 
drugs, the European internal security strategy (COSI) and the 
European action plan for HIV/AIDS, in order to ensure that 
these are appropriately addressed.
A major task in 2014 is the second step to overhaul the 
agency’s main reporting tools to make them more relevant to 
be distinguished from activities which may be scaled down or 
delayed without preventing the agency from fulfilling its core 
mandate. It is also possible to identify important tasks that are 
so advanced or so closely integrated with indispensable 
activities that removing them would not be rational or cost 
efficient. Thus, in drawing up this work programme all 
proposed activities have been classified across three levels 
– L1, L2, L3.
L1 – These are defined as ‘must do’ tasks indispensable for 
the agency to fulfil its minimum institutional obligations. These 
are core tasks related to the annual production of the main 
outputs, legal obligations (such as those arising from the 
recast Regulation, Council Decision, the EU 
pharmacovigilance legislation) or tasks necessary to ensure 
that reporting tools and processes remain fit for purpose. L1 
also applies to necessary institutional and support activities, 
including support to the EMCDDA’s statutory bodies and 
organisation of the statutory meetings, production of the 
institutional publications and management tasks.
L2 – These are core tasks necessary to achieve key 
commitments set out in the three-year work programme. Most 
of these tasks are so integrated with L1 activities that 
separating them out would not make sense in terms of the 
costs to benefits of pursuing them. An L2 grading is also given 
when activities commenced in previous years are so advanced 
that the bulk of resources required have already been invested 
and so it would not be cost effective to leave them 
uncompleted.
L3 – These activities are important for the agency’s mandate 
but in the event of further resource constraints they can be 
potentially removed, scaled down or postponed without 
significantly impacting on the agency delivering its minimum 
institutional obligations in 2014 (i.e. L1 activities).
The target for the EMCDDA is to achieve 100 % of the L1 
activities, minimum 80 % of the L2 activities and minimum 
50 % of the L3 activities (see Annex III, key performance 
indicator 10.2.1.)
I  Continuing to progress during a challenging period — activities in 2014
The agency’s scientific work programme concentrates on 
providing a high-quality analysis of the European drug 
situation. For relatively well developed areas, the focus is on 
better exploiting the analytical potential of the considerable 
data resources now held by the EMCDDA. Thus emphasis is 
placed on multi-indicator analysis and bringing together 
responses and situation data sets. An example of this is the 
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EU bodies. This is in accordance with the interinstitutional 
Joint Statement/Common approach on EU decentralised 
agencies as adopted in July 2012 by the European Parliament, 
the Council and the Commission. Fully in line with this 
document, the EMCDDA has recently stepped up its efforts to 
strengthen cooperation and build synergies with the European 
Maritime Safety Agency (EMSA), with a view to developing 
opportunities for increased effectiveness, efficiency gains and 
cost savings provided by the geographical proximity of the 
headquarters of the two agencies in Lisbon, while safeguarding 
the autonomous legal personality and capacity assigned to 
each agency by the EU legislator via the respective basic act. A 
number of areas for synergies were identified in 2013, namely 
human resources management, logistics and infrastructure 
management, and information and communication 
technologies. Following endorsement by the Directors, the 
concerned services of both agencies have already started 
implementing the required actions, and the process will be 
further developed and expanded throughout 2014.
Synergies with other agencies also include continuing the 
close collaboration and exchange of experience and good 
practices carried out in the context of the interagency 
networks, such as the Performance Development Network 
(PDN), the Inter Agency Legal Network (IALN), the network of 
accounting officers (IAAN), Heads of Communication and 
Information network (HCIN), etc.
Furthermore, the EMCDDA has started to develop its 
performance measuring system, which will also contribute to 
increasing effectiveness and efficiency in working practices 
and in the implementation of the agency’s work programme. 
Key performance indicators (KPIs) for three areas are already 
in place for the 2014 Work Programme and KPIs for all areas 
are being developed.
These measures will be complemented by effective use of 
budget planning and management tools and the development 
of the activity-based budgeting approach to further improve 
efficient allocation and use of resources earmarked for the 
implementation of the work programme.
In the area of Information and communication technology 
(ICT), developing ICT governance will remain central to 
support the agency in implementing its work programme and 
achieving the expected results and targets set for 2014. 
Increased use of the ICT Steering Committee will be made in 
2014, in order to guide investments in this key area.
Another area of importance in 2014 is business continuity, i.e. 
the process of preparing for either planned or unforeseen 
events that can cause interruption in the agency’s activities. 
Not only because it makes good business sense, but also 
because it one of the Internal Control Standards (No 10) 
adopted by the EMCDDA’s Management Board. To this end, 
the future needs, key partners and target audiences. The 
EMCDDA’s web presence will be developed within a new 
integrated and thematic approach. The Statistical bulletin will 
be revised within the overall integrated framework and work 
will start on a new approach for presenting national data. This 
is a particularly timely development as it requires a close 
working partnership with the Reitox network. As the EMCDDA 
can only report the data it receives from Member States, the 
approach adopted will have to be informed by any changes in 
the system’s capacity. It may also be possible to achieve 
efficiency savings by reviewing current reporting practices and 
reducing efforts in areas that have proved unproductive. The 
fact that the agency needs to do more to support the expert 
networks it depends on and engage more with the practice 
community is reflected in the 2014 tasks. A new community 
area will facilitate ongoing conversation with and between 
experts working on drug issues in Europe. The new web 
strategy will provide increased visibility and access to data on 
responses to the drugs programme. It will also allow the 
agency to give greater prominence to the work it does to 
identify and disseminate best practice, including further 
development of the Best practice portal. The successful 
partnership with the Cochrane collaboration will continue with 
two joint evidence reviews planned in 2014. The EMCDDA’s 
support for European scientific studies, research networking 
and dissemination will also be further developed.
I Focusing on efficiency
Ensuring that the agency’s resources are used in the most 
efficient, effective and economical manner will be a priority for 
all areas of work. This is one of the EMCDDA’s three top-level 
commitments for 2013–15, as emphasised in its three-year 
strategy and work programme. This becomes increasingly 
important for the implementation of the 2014 Work 
Programme, with the substantial budget cuts that the agency 
will probably face due to the significant decrease in the EU 
subsidy allocated.
In order to cope with this critical situation, the EMCDDA has 
already taken several important measures with regard to its 
operations in 2014. First of all, it has prioritised all planned 
activities as detailed earlier. Another measure planned for 
2014 is to continue to rationalise the use of existing material 
resources through improved logistics and infrastructure 
management. A detailed plan of actions which continues the 
work carried out in 2013 will be further implemented, with the 
objective of reducing utility costs as much as possible by 
optimising the use of space and existing facilities. The target is 
to decrease these costs by a further 4 % in 2014.
To this end, an important contribution to achieving further 
efficiency gains will be brought by building synergies with other 
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Furthermore, following the agency’s strong commitment to 
developing its performance measurement system, for the first 
time, well-defined performance indicators are presented in the 
document (see Annex III). These indicators represent the first 
step in the implementation of the action plan endorsed by the 
Management Board, which aims to introduce performance 
indicators for all the areas of work, planned for completion in 2015.
The EMCDDA 2013–15 strategy and work programme 
envisages a number of key outputs which were planned to be 
published by the end of the 2015. This planning was based on 
the resources estimates that were available when preparing 
the document and has been reviewed in light of the current 
financial perspective.
As a consequence, the following key outputs will no longer be 
produced:
–  In-depth topical review on drugs and prison (EMCDDA 
Insights series) and accompanying guidelines
–  State-of-the-art scientific review on drug policy challenges 
for the twenty-first century (EMCDDA Monograph series)
–  State-of-the-art scientific review on drug prevention 
(EMCDDA Monograph series).
the Business continuity plan (BCP) adopted in July 2013 will 
be constantly updated to be coherent with the EMCDDA’s 
structures, resources and workflows and all staff will be 
trained on the content of the BCP and their respective 
responsibilities. Training on the BCP will be included in the 
EMCDDA training annual framework, resources permitting.
I Structure of the work programme
This work programme mirrors the structure of the EMCDDA 
2013–15 strategy and work programme. For each of the 12 
main areas, detailed activities and expected outputs/results 
were planned to contribute to the achievement of the specific 
objectives and goals set up by the three-year strategic 
document. This follows the approach introduced by the 2013 
work programme and ensures continuity in the agency´s 
multi-annual planning and facilitates monitoring of results.
In addition, the 2014 Work Programme clearly defines several 
levels of priorities (see earlier section) corresponding to the 
planned activities. This responds to the need to adjust the 
work to potential further resources constraints and it is in line 
with the recommendations formulated by the EMCDDA´s 
Management Board and by the agency’s Scientific Committee.
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Key outputs to be published in 2014 and their intended audience
Output:
Target audiences:
Policy Science Practice Citizen
Annual reporting 
European Drug Report package:
n Trends and developments (printed, 23 languages)
n Perspectives on drugs (PODs) (online, EN)
n Statistical bulletin (online, EN)
n Country overviews (online, EN)
n Interactive application (app, EN)
n Press notes (23 languages)
3 3 3 3
EMCDDA online
Ongoing development and content updating of the EMCDDA’s public website. This includes 
regular and cyclical content updating including:
n  Topical content areas (policy and law, health and social interventions, indicator 
resources pages, research, drug profiles, international cooperation, etc.)
n The European database on new drugs (EDND) (online, restricted)
n Best practice portal (including EIB and EDDRA)
n News and events
(online, EN, with some multilingual sections)
3 3 3 3
Technical publications
EMCDDA Insights
n Treatment of cannabis-related disorders (printed, PDF, EN)
3 3 3
EMCDDA Manuals (Guidelines, standards and protocols)
Technical guidelines:
n PDU – revised guidelines (online, PDF, EN)
3 3
EMCDDA Papers (online, PDF, EN)
n Drug trafficking penalties
n Drug policies of large cities
n Polydrug use: an analysis of drug combinations in school and adult populations
n New perspectives in environmental prevention
n National drug policy
n Drug supply and external security: EU policy overview
n Mortality among drug users in Europe; a combined multi-country analysis
3 3 3
EMCDDA Reports (institutional and implementation reports and joint publications)
n General Report of Activities 2013 (printed, PDF, EN)
n EMCDDA 2014 Work Programme (online, PDF, EN)
n 2013: A year in review (printed, EN)
Outputs related to the implementation of the Council Decision 2005/387/JHA:
n EMCDDA–Europol report on the implementation of the Decision (Article 10 report)
n EMCDDA–Europol Joint Report and risk assessment (if necessary) 
(online, PDF, EN)
3
3
3
3
3
3
3
3
Drugnet Europe newsletter (printed, PDF, EN, four issues) 3 3 3 3
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I  II.1 Data collection, analysis and quality assurance
I Overview
The activities in 2014 continue earlier work to ensure a robust 
data collection system which is coherent and results in reliable 
and valid data. Monitoring the drug situation through the 
standardised collection of data is central to the work of the 
agency. The data collection and analysis, along with the 
associated tasks to ensure reliability, validity and transparency, 
are a resource for our external stakeholders and are the 
foundations on which the outputs of the agency are built.
Formalising quality assurance procedures and meeting the 
demands of a changing set of outputs are underlying themes 
of the work, though many activities are inter-related and 
address both issues.
On the technical side of the data collection, pending the 
allocation of funds, focus will be on making improvements 
with the resources available in-house. The evolution of Fonte 
will prioritise the demands made by the new TDI data 
collection to ensure functionality and continuity. In addition, 
the data flow within the EMCDDA will be addressed to better 
generate datasets that can be used for querying and analysis, 
which in turn will support the new products and improve 
efficiency.
The cyclical work of developing data collection tools and 
adjusting templates will concentrate on prisons and mortality 
cohorts during 2014, with reflection on the changes 
implemented for the 2013 data collection for problem drug 
use, the behavioural indicators related to drug-related 
infectious diseases and targeted surveys. Revision and 
development of the supply side indicators will require 
adjusting existing data collection tools. The revision of tools in 
the area of health and social responses will allow further 
implementation of the treatment data collection strategy.
The development of the European Drugs Report (EDR) 
package will continue, with delivery on the web being a central 
theme. The early production and analysis of the data will be 
maintained. Changes to both the content and presentation of 
the Statistical bulletin as a result of the 2013 review will be 
implemented. Given the calendar, the changes to the 
Statistical bulletin will become fully apparent in 2015. 
Furthermore, a process of review of the country overviews will 
commence as part of the wider consideration of country-level 
data (see Main area 9, priority intervention 9.2.2.).
Quality assurance is relevant to all aspects of the data 
management process and the analysis of data. Receiving 
particular attention is the better documentation of 
computations and of data limitations in the methods and 
definitions of the Statistical bulletin and the provision of more 
detail on simple analyses of the data. Both will be components 
of the Statistical bulletin review. Efforts will continue to 
formalise the data checks with other data sources, both 
internal and external, involving cooperation with UNODC, 
ECDC and WHO.
The first submission of data under the revision of the TDI 
occurs in 2014, and with it comes a range of both technical 
and analytic challenges. Work on Fonte is necessary to ensure 
that the data can be submitted and validated. The tables and 
graphs constructed in the Statistical bulletin will be reviewed 
and a new set of SQL programmes will be developed to 
extract the data necessary to construct basic tables and 
graphs for analysis. This work is essential to ensure the 
continued delivery of TDI.
II. MAIN AREAS OF WORK IN 2014
Monitoring and reporting on the  
drugs problem in Europe
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A coherent, reliable and valid data collection system, underpinned by a quality assurance framework
Goal 2013–15
Specific objective 1.1: Improve data collection instruments and processes
Priority interventions Planned activities Expected outputs/results
1.1.1. Ensure the coherence, efficiency and 
quality of reporting tools and processes
1.1.1.1. Review and revise reporting package to 
ensure efficiency, and match priorities and 
resources (in coordination with national focal 
points (NFPs)) (L1)
n  Streamlined reporting package developed 
and implemented
n  Work plan and tools adopted for 2015
1.1.2. Annual data collection exercise 1.1.2.1. Implement annual reporting cycle (L1) n  NFPs supported in data submission 
(guidelines and tools)
n  2013–14 data cycle implemented
n  2014–15 data cycle launched
1.1.2.2. Fonte maintenance and update: revise 
templates (as required) (L1)
n  Standard tables updated as required
n  Templates and processes adjusted to 
improve reporting of supply area
n  Data collection tools revised to reflect 
developments in Treatment strategy
1.1.2.3. Rationalise collection of ‘quality of 
intervention’ measures (L3)
n  Small expert review meeting resulting in a 
rationalised SQ27 (part II) (integrating 
questions from SQ23–29)
n  Streamlined approach to updating profile 
data
n  Reduced reporting burden 
1.1.2.4. Feasibility test of using composite 
scores for prevention (L3)
n  Consultation with NFPs
1.1.3. Maintain Fonte reporting system and 
data warehouse
1.1.3.1. Maintain databases and tools (L1) n  Systems for drug data collection operational
n  Method for handling the new TDI template 
and validations within Fonte developed
1.1.3.2. Improve automatic data submission 
tools and data extraction tools (L2)
n  Improved functionality for NFPs
n  TDI template to generate XML for direct 
input into Fonte
n  Datasets that can be queried or analysed 
more easily
1.1.3.3. Review and reconcile historical data 
sets in supply area (L2)
n  Ongoing validation and update of historical 
data series (resource dependent) 
Specific objective 1.2: Strengthen the quality assurance framework to support data collection, analysis and reporting
Priority interventions Planned activities Expected outputs/results
1.2.1. Implement a cross-indicator methods 
for validation and analysis
1.2.1.1. Implement coherence checks, 
combined analysis and develop (where 
possible) indexes (L3)
n  Internal working document(s)
n  Improved multi-indicator analysis
n  Improved modelling of service coverage 
1.2.2. Review, rationalise and improve quality 
assurance measures for data collection 
1.2.2.1. Implement cross-checking of data 
between the National reports and the Statistical 
bulletin tables (sub-set of indicators) (L2) 
n  Improved validity and reliability of the data 
received
1.2.2.2. Monitor the quality of the data reported 
by NFPs and provide feedback (L2) 
n  Quality reports prepared for all NFPs
1.2.2.3. Carry out (where possible) coherence 
checks with external data sources (L3)
n  Coherence problems identified and rectified
1.2.3. Develop a statistical quality framework 
for the analysis, manipulation and reporting of 
data within the EMCDDA
1.2.3.1. Produce the 2014 Statistical 
bulletin (L1)
n  2014 Statistical bulletin published online
1.2.3.2. Review the Statistical bulletin to better 
complement the new European Drug Report, 
increase web functionality, and improve access 
to national data (L1)
n  Improvements to web functionality 
documentation introduced in 2014
n  New Statistical bulletin structure developed 
and pilot work conducted for implementation 
in 2015
1.2.3.3. Implement improvements to the 
reporting of ‘ratings’ in structured 
questionnaires (L1)
n  Framework for expert ratings introduced
1.2.3.4. Implement framework for statistical 
quality assurance (L2)
n  Data coherence group operational
n  Increased oversight of information requests
n  Improved documentation of methods and 
computations
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The added value of the EMCDDA’s epidemiological information 
is to a considerable extent based on the work of national focal 
points and the networks of national experts in the respective 
key indicators. An important task during the 2013–15 work 
programme is the ongoing maintenance, reinforcement and 
development of these networks. This is achieved through 
continuous contact with their members, giving them scientific 
advice and support, and by holding annual meetings of the 
expert networks. Furthermore, the quality and consistency of 
epidemiological monitoring at European level is based on 
implementation of the common EMCDDA standards and key 
indicators in Member States. This implementation needs the 
joint and continuous effort of NFPs, national experts and the 
EMCDDA and is an ongoing core task for them. Many third 
countries (e.g. candidate countries, neighbouring countries 
and others) are using the key indicators as models for 
developing their own drug monitoring strategies and the 
EMCDDA support provided is valuable to these countries.
The analysis of the data collected by Member States and 
reported to the EMCDDA will be reinforced during 2014. The 
annual key indicator expert meetings will play an important 
role in increasing the agency’s analytical capacity. The 
meeting format will be further improved to allow more analysis 
within and across indicators and extended to include 
information on responses to drug problems. These meetings 
will aim to analyse existing national and European data series 
but also to identify the more recent trends in drug use and 
problems.
Promoting and facilitating harmonised analysis at national 
level facilitates and enhances common European analysis. 
During 2014, and building on work done in 2013, concise 
national plans of analysis will be developed. These plans will 
include basic common guidelines and outputs to be produced 
at national level, which can facilitate national outputs and 
collation of data at European level.
Psychiatric co-morbidity is an essential dimension for 
understanding drug problems, their evolution and the possible 
outcomes of treatment, including the chances of recovery. An 
in-depth analysis of this domain will be concluded in 2014, 
with the publication of an Insight in 2015.
Web resources have become an essential component for 
presenting and disseminating information. Improving the 
usefulness and accessibility of the epidemiological 
information and analysis will be a focus in 2014 within the 
overall framework of website developments.
I  II.2 Monitoring and understanding drug use and problems: key indicators and epidemiology
I Overview
An objective and reliable knowledge and understanding of the 
drug situation in terms of prevalence and patterns of use, risk 
factors and health and social consequences is a prerequisite 
for developing policies and interventions and for evaluating 
their outcomes and effectiveness. Therefore, the 
epidemiological monitoring of prevalence and patterns of drug 
use and of its health and social consequences has been at the 
heart of the EMCDDA´s work from its establishment.
The epidemiological monitoring is based on a range of core 
indicators, called epidemiological key indicators (KIs) that 
include: the prevalence and patterns of drug use in the general 
population (GPS), the prevalence and patterns of problem 
drug use (PDU), the number and characteristics of drug users 
contacting drug services – in particular treatment services 
(TDI), the number of drug-induced deaths and mortality 
among drug users (DRD), and the infectious diseases related 
to drug use (DRID).
Our goal for the 2013–15 work programme is to provide an 
improved overview of the European drug situation by 
enhancing analysis of the epidemiological information and of 
the corresponding key indicators. Work in 2014 will build on 
the activities started in 2013, with new analytical initiatives 
also being developed.
Considerable methodological progress has been attained in 
previous years, but to maintain the epidemiological key 
indicators fit for purpose and in line with evolving information 
needs, some methodological work remains necessary and 
some data collection tools (Standard Tables) need to be 
adapted.
Polydrug use is an increasingly common phenomenon across 
Europe, and it can lead to increased risks and harms and there 
is a need for appropriate specific responses. Analysis of 
polydrug use is therefore a priority, and in 2014 this will be 
improved and expanded, in particular in population survey 
data, both in adults and in school children (in cooperation with 
ESPAD). Improving cooperation with the ESPAD project is one 
of the objectives of the three-year work programme. During 
2014 this cooperation will be maintained and reinforced, 
following the agreement to scale up cooperation between the 
project and EMCDDA.
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Provide an integrated and insightful overview of the European drug situation by enhancing analysis of the epidemiological 
key indicators, including cross-indicator analysis and combined analysis with other sources of information, while ensuring 
the quality of the information collected by Member States and the EMCDDA
Goal 2013–15
Specific objective 2.1: Ensure progress in the methodological development of the epidemiological key indicators (KIs)
Priority interventions Planned activities Expected outputs/results
2.1.1. Ensure key indicators methods and tools 
remain fit for purpose
2.1.1.1. Revise tools for data collection on 
treatment prevalence based on TDI data 
collection (L2)
n  Treatment prevalence module finalised
2.1.1.2. Review and revise if necessary 
monitoring approach to drug-related infectious 
diseases (DRID) to ensure they remain ‘fit for 
purpose’ (L2)
n  DRID review exercise completed (internal 
working document) and tools revised (as 
required)
2.1.1.3. Develop consensus with relevant 
partners on minimum core set of alcohol use 
variables to include in drug surveys (in the 
context of polydrug use) (L2)
n  Set of core alcohol variables identified
n  Consensus meeting organised as a satellite 
to GPS expert meeting 
2.1.1.4. Improve comparability of data available 
on drug use in prisons (L3)
n  Common questions launched and available 
for piloting in interested countries
2.1.1.5. Audit national survey data collected on 
new psychoactive drugs (L3)
n  Analysis presented at the GPS annual expert 
meeting
n  New questionnaire set established
2.1.2. Scale up cooperation with ESPAD 
project
2.1.2.1. Contribute to the launch of the 2015 
ESPAD study and ensure ESPAD coordination 
(L2)
n  EMCDDA support provided to coordination 
tasks, questionnaire development and 
preparatory activities for 2015 
2.1.2.2. Support analysis and dissemination 
(L2)
n  Joint analysis on polydrug use with focus on 
alcohol and medicines
n  Integration of ESPAD data into the EMCDDA 
website
Specific objective 2.2: Support the implementation of the key indicators through ongoing monitoring and provision of technical 
guidance and training
Priority interventions Planned activities Expected outputs/results
2.2.1. Actively monitor implementation of KIs 
and identify implementation needs
2.2.1.1. Monitor the implementation status of 
KIs in all countries (L2)
n  Annual review conducted and follow-up 
implemented as needed 
2.2.2. Provide expert advice and training to 
support the countries, as needed 
2.2.2.1. Provide scientific and technical advice 
and support to national experts and the NFPs 
(L2)
n  Training delivered as required, based on 
identified needs and availability of resources 
2.2.3. Support key indicator implementation 2.2.3.1. Support countries in implementation of 
epidemiological key indicators, in particular for 
the implementation of the new TDI protocol 
(version 3.0) (L2)
n  Assistance provided (based on availability of 
resources)
2.2.4. Support the implementation of KIs in 
third countries and international efforts to 
improve reporting capacity (see objectives 
8.5.3 and 8.4.2 for details)
2.2.4.1. Provide training and support (where 
appropriate and based on available resources) 
(L3)
n  Training and advice provided (see also 
activity 8.5.3.1 – Handbook II) 
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Specific objective 2.3: Maximise the value of key indicator information through analysis to provide a comprehensive, relevant 
and multi-source understanding of contemporary patterns of drug use, trends and related health and social consequences
Priority interventions Planned activities Expected outputs/results
2.3.1. Develop analytical capacity, maintain KI 
expert networks, and introduce more 
integrated and efficient working practices 
2.3.1.1. Carry out analysis of the European drug 
situation by using KI data and maintain expert 
networks, through meetings, networking and 
capacity building activities (L1)
n  Annual European expert meetings organised 
and results disseminated
n  Quality assurance guidelines for meetings 
implemented
n  Cross-indicator analysis and networking 
supported (technical collaboration and 
online resources)
2.3.2. Improve exploitation of data through 
standalone, cross-indicator, and cross-area 
analysis
2.3.2.1. Conduct annual exercise to identify 
priority questions requiring analysis and task 
internal work group(s) (L1) 
n  Core analysis completed to inform EMCDDA 
outputs
n  Cross-indicator and cross-area analysis
n  Long-term trends analysis conducted
2.3.2.2. Carry out analysis of harmonised 
national GPS databases (L2)
n  New topic identified and exploratory analysis 
conducted 
2.3.2.3. Improve analytical value of existing PDU 
estimates (L2)
n  Critical review and harmonisation exercise of 
estimates conducted
2.3.2.4. Finalise analysis of trends in cannabis 
treatment demand (L2)
n  Technical report on patterns and trends of 
cannabis clients
2.3.2.5. Explore potential of wastewater 
analysis as an indicator to estimate population 
drug consumption (L2)
n  Concept paper drafted (internal working 
document)
n  Findings of ‘Demonstration project’ available 
online 
2.3.2.6. Prepare in-depth topical review on 
psychiatric co-morbidities (EMCDDA Insights 
series) (L2)
n  EMCDDA Insights on psychiatric co-
morbidities prepared
2.3.2.7. Conduct selected cross-indicator 
analysis in different domains (L2)
n  Update analysis on trends, patterns and 
prevalence of injection on TDI and PDU
n  Technical report on estimation of HIV 
mortality attributable to drug injection
2.3.2.8. Improve understanding of market size 
(L2)
n  Multi-indicator model of market size 
developed and preliminary estimates 
calculated (selected drugs) 
2.3.2.9. Improve timeliness and access to 
information on drug injecting, health 
consequences and service development (with 
input from partners) (L3)
n  Annual update on trends and developments 
(web based) 
2.3.2.10. Improve reporting capacity for 
non-fatal health consequences of drug use (L3)
n  Pilot analysis of emergencies related to 
cannabis conducted (project report 
prepared)
n  Methodological developments in drug-
related emergencies followed and strategy 
paper finalised
n  Thematic web area conceptualised and 
implemented
2.3.3. Support analytical capacity 
development at national level 
2.3.3.1. Develop standard analysis plans to help 
NFPs improve reporting and analysis (L3)
n  Analysis plans tested for selected indicators
2.3.4. Rationalise and improve web-based 
information on the drug situation
2.3.4.1. Map thematic areas and develop 
website content on key themes, methods and 
national data profiles in context of the 
integrated EMCDDA website framework (L1)
n  Map exercise completed and thematic 
content developed in the EMCDDA website 
framework
n  Prototype of national epidemiological 
profiles developed
n  Quality assurance procedures introduced 
(updating and content)
n  Expert users’ area(s) launched
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reviewed and options for updating EMCDDA resources will be 
explored.
Monitoring demand reduction requires not only reporting on 
numbers of interventions, but also reporting on the coverage 
and quality of interventions. This information helps Member 
States identify gaps in current service provision and 
contributes to an assessment of the national situation on the 
responses side. In 2014, we will further implement the new 
treatment data collection and analysis strategy. Treatment 
system maps will be consolidated, aiming to provide a better 
understanding of national treatment systems and the number 
of persons reached. Work on the target-and-indicator 
framework will continue in 2014 and as a pilot exercise we will 
monitor the implementation of the joint ECDC–EMCDDA 
‘Guidance on the prevention of infectious diseases among 
people who inject drugs’.
We will continue to prioritise our work to identify best practice 
in the drugs field and our ongoing dialogue with the scientific 
and practice community will ensure that we benefit from 
state-of-the-art understanding of the available evidence of 
effectiveness. Our successful collaboration with the Cochrane 
group will be continued in 2014 and the outcome of this 
project will allow the information provided through the Best 
practice portal to be expanded and updated. In addition, the 
Best practice portal will be revamped in order to improve its 
usability and functionality. We will also finalise the work on the 
in-depth topical review on hepatitis C treatment for 
publication in early 2015.
I  II.3. Monitoring demand reduction responses applied to drug-related problems
I Overview
Describing the demand reduction measures that Member 
States take to address drug problems is a core aspect of the 
EMCDDA’s work. These interventions span prevention, 
treatment, harm reduction and social reintegration.
Making the latest information in the demand reduction area 
available online is a core task for 2014, reflecting the move 
towards increased online dissemination. The health and social 
responses profiles, which have been a highly-valued 
interactive element on the EMCDDA website in 2013, will be 
updated and further developed. These country-by-country 
‘integrated response profiles’ provide an overview of how 
countries in Europe are responding to drug use in the areas of 
treatment, harm reduction, social reintegration and the prison 
environment.
For the prevention area we will continue to invest in areas that 
are likely to become important for future prevention work in 
Europe. We will continue our work on environmental 
prevention and publish an EMCDDA paper on this topic. In 
addition, the latest information on early intervention and 
coordinated programming will be reviewed and made available 
online. Existing source material in the prevention area will be 
To support high-quality service development by producing information and analysis on demand reduction interventions and 
best practices
Goal 2013–15
Specific objective 3.1: To monitor prevention provision, implementation and outcomes and to improve reporting on important 
areas where information resources are lacking
Priority interventions Planned activities Expected outputs/results
3.1.1. Provide an ongoing overview of drug 
prevention provision
3.1.1.1. Analyse and report findings from drug 
prevention area and develop thematic area 
within context of the integrated website 
framework (L1)
n  Key analyses conducted and improved web 
resources developed, including up-to-date 
prevention profiles 
3.1.2. Develop analysis on environmental 
prevention 
3.1.2.1. Monitor developments in environmental 
prevention (L2)
n  Expert meeting organised and report 
available
n  EMCDDA Paper published
3.1.3. Provide updated information on early 
intervention
3.1.3.1. Review the evidence on brief 
interventions and motivational interviewing (L2) 
n  Feasibility report and evidence review (in 
collaboration with the International Network 
on Brief Interventions for Alcohol and Other 
Drugs) 
3.1.4. Develop information on coordinated 
programming
3.1.4.1. Review multidimensional programmes 
and strategies across behavioural domains (L3)
n  Technical review on programmes with 
multiple outcomes 
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Specific objective 3.2: To improve the monitoring and analysis of treatment, harm reduction and social reintegration 
interventions and provide an integrated model for understanding service provision in Europe
Priority interventions Planned activities Expected outputs/results
3.2.1. Provide an ongoing overview of drug 
treatment, harm reduction and social 
reintegration
3.2.1.1. Analyse and report findings from 
responses area and develop thematic area 
within context of the integrated website 
framework (L1)
n  Key analysis conducted and improved web 
resources available, including online 
products on treatment, harm reduction and 
social reintegration 
3.2.1.2. Develop conceptual framework for a) 
monitoring the public health responses to new 
psychoactive substances; and b) Internet-based 
treatment (L3) 
n  Internal working document(s) available 
3.2.2. Implement the new treatment data 
collection and analysis strategy 
3.2.2.1. Improve estimates of treatment 
availability (L2)
n  Feasibility test of facility survey questions
n  Expert meeting 
3.2.2.2. Support countries in improving 
estimates of the total number of people in 
treatment (L2) 
n  Methodological toolkit adopted and available 
for use by countries
3.2.3. Conduct comparative analysis of drug 
treatment systems in Europe 
3.2.3.1. Develop a conceptual framework for 
analysis of national treatment systems (L2) 
n  Expert meeting
n  Preliminary analysis conducted 
3.2.4. Develop and test health and social 
responses target-and-indicator frameworks 
3.2.4.1. Refine target-and-indicator framework 
concept, using multiple-indicator approach 
(based on work from 2013) (L2)
n  Technical paper: Target-and-indicator 
framework
n  Pilot exercise conducted (infectious disease 
prevention)
Specific objective 3.3: To identify and support dissemination and knowledge exchange on best practices
Priority interventions Planned activities Expected outputs/results
3.3.1. Conduct state-of-the-art and evidence 
reviews
3.3.1.1. Finalise in-depth topical review on 
hepatitis C treatment (L2) 
n  In-depth topical review on hepatitis C 
treatment prepared (EMCDDA Insights 
publication for 2015)
3.3.1.2. Carry out evidence reviews in important 
intervention areas (in collaboration with the 
Cochrane Group) (L2) 
n  Review of treatment and pregnancy 
conducted, Best practice portal updated and 
paper submitted
n  Review of Naloxone and overdose 
conducted, Best practice portal updated and 
paper submitted 
3.3.1.3. Update synthesis of evidence 
resources for demand reduction interventions in 
the Best practice portal (BPP) (L2) 
n  Modules updated
n  New module, on psychiatric co-morbidity 
introduced
3.3.1.4. Disseminate emerging evidence in the 
prevention area (L3) 
n  Existing source material reviewed, gaps 
identified and options for updating resources 
explored 
3.3.1.5. Conduct a literature review on the 
concept of route to recovery from drug 
dependence (L3) 
n  Technical paper prepared
3.3.1.6. Conduct a meta-analysis of long-term 
observational studies to analyse survival rate 
and recovery rate of drug users (L3) 
n  Study protocol completed
3.3.2. Disseminate knowledge on best 
practice and improve functionality and 
usability of online tools 
3.3.2.1. Revise the BPP website in line with the 
integrated website framework (L1) 
n  Redesigned BPP in line with the principles of 
the knowledge translation, enhancing the 
training issues: prototype ready
3.3.2.2. Improve usability of BPP (L1) n  Interactive tool developed to map quality 
assurance approaches
3.3.2.3. Support the European Union 
institutional activities to promote quality 
standards (L2) 
n  Standards available online
n  Report prepared on adoption of standards at 
national level
3.3.2.4. Create a new inventory of evidence-
based projects and experience of 
implementation (L3) 
n  Prototype ready 
3.3.2.5. Conceptualise and evaluate long-term 
options for the dissemination of best practices 
(L3) 
n  Options strategy drafted
3.3.3. Conduct analysis to identify gaps in the 
evidence available for interventions 
3.3.3.1. Finalise and disseminate the list of 
research questions resulting from the gap 
analysis conducted in 2013 (L2) 
n  List of research questions disseminated 
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enforcement officials at national and EU levels. In 2014, the 
EMCDDA will undertake preparatory work with Europol and 
the Member States for the second edition of the report. The 
analysis in the second report will be strengthened by the work 
on the multi-indicator model for market size estimates.
Central to the work of the EMCDDA in the area of drug supply 
and drug supply reduction, is the EU Reference Group on drug 
supply data. Following its constitution and the first meeting of 
this group in 2013, it will be essential in 2014 to ensure its 
continuity and sustainability. With a membership potentially 
large in terms of areas of expertise, and working modalities 
flexible to accommodate different objectives — including 
support to indicator development, contextualisation of routine 
data, updates on supply reduction interventions, and 
identification of emerging trends — particular care will be 
dedicated to making best use of it within a context of limited 
resources. One of the tasks of the group in 2014 will be to 
launch national consultations on the EMCDDA proposal for a 
revised reporting instrument on drug seizures at EU level.
In addition, links with the law enforcement community will be 
reinforced through the EMCDDA’s training activities in 
partnership with CEPOL (European Police College). This will 
ensure that the European law enforcement community has 
access to relevant EMCDDA expertise and products in order 
to support their work.
In parallel to this, the EMCDDA will fulfil the tasks assigned to 
it in the Operational Action Plans (OAPs) within the EMPACT 
framework developed under the new EU policy cycle for 
organised and serious international crime 2013–17 within the 
Council’s Standing Committee on operational cooperation on 
internal security (COSI) of the European Union. The EMCDDA 
will provide contributions in the field of synthetic drugs, 
cocaine and heroin; the agency will also provide support to 
Europol for the follow-up of activities initiated under the 
previous policy cycle (2012–13), in particular on the reporting 
of synthetic drugs production sites.
I  II.4. Monitoring drug supply and supply reduction interventions
I Overview
In 2014, the EMCDDA will primarily focus on the 
developmental work to improve tools and concepts for 
reporting on drug supply (drug markets, drug-related crime 
and drug supply reduction), with a particular focus on existing 
data sets at EU level. This supports Action 16 of the EU action 
plan on drugs (2013–16) which calls for the development and 
progressive implementation of key indicators on drug supply 
by standardising, improving and streamlining data collection 
in this field, building on currently available data, and is in line 
with the draft Council conclusions on improving the 
monitoring of drug supply in the European Union (2013).
With a view to addressing the lack of comparable and reliable 
data on drug supply in general, and as a follow-up of the 2012 
proposal to develop three key indicators in the areas of drug 
markets, drug-related crime and drug supply reduction, and of 
the roadmap which prioritised existing data sets, the EMCDDA 
in consultation with Europol will scale up the work in this area. 
This will include the preparation of a draft proposal for a 
revised reporting instrument on drug seizures, as well as 
technical reviews in the areas of drug production facilities, 
drug prices and drug purity and contents, while synergies with 
Eurostat will be sought on the EU reporting on drug-law 
offences. In addition, specific investments will be continued in 
the area of drug supply reduction, where knowledge and 
indicator development is more limited, and the cooperation 
with Eurojust will be strengthened in order to produce a joint 
analysis of cross-border trafficking and judicial cooperation in 
the field of drugs in the EU.
The first EU drug markets report (2013) was widely recognised 
as providing a major contribution to both understanding drug 
supply and defining priorities for policymakers and law-
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Provide the European Commission (EC) and the Member States with a comprehensive overview of the supply of illicit drugs 
into Europe and of the responses developed to respond to it
Goal 2013–15
Specific objective 4.1: Develop European key indicators and complementary information resources for understanding drug 
markets, drug-related crime and drug supply reduction
Priority interventions Planned activities Expected outputs/results
4.1.1. Improve the quality and comparability of 
data on drug supply (drug markets, drug-
related crime and drug supply reduction) 
4.1.1.1. Improve tools and concepts for 
reporting drug seizures (L1) 
n  Comparative analysis of reporting practices 
in Member States (based on the mapping 
carried out in 2013)
n  Technical background paper available from 
pilot study to inform draft proposal for a 
revised reporting tool on drug seizures at EU 
level
n  Consultation exercise with national data 
providers launched 
4.1.1.2. Improve tools and concepts for 
reporting on drug production facilities, through 
pilot work on cannabis cultivation (L2) 
n  Technical background paper available
n  Conceptual overview and proposal for 
reporting framework developed
n  Mapping exercise launched
n  Review of enforcement strategies launched
4.1.1.3. Improve tools and concepts for 
reporting on drug production facilities, through 
pilot work on synthetic drugs production sites 
with Europol (L1) 
n  Analytical queries developed
4.1.1.4. Improve tools and concepts for 
reporting on drug prices (L3) 
n  Conceptual plan and proposal for reporting 
framework developed
n  Expert meeting organised
n  Mapping exercise launched
4.1.1.5. Improve tools and concepts for 
reporting on drug purity and contents (L3) 
n  Conceptual plan and proposal for reporting 
framework developed
n  Expert meeting organised
n  Mapping exercise launched
4.1.1.6. Launch the development of the 
sub-indicator drug-law offences (L3) 
n  Coordinated approach with Eurostat 
established
n  Conceptual plan and proposal for reporting 
framework developed
n  Expert meeting organised
4.1.2. Improve understanding of drug supply 
reduction activities 
4.1.2.1. Update and report on drug squads at 
EU level (L3) 
n  Expert meeting organised
4.1.3. Develop cooperation with external 
partners on drug supply indicators
4.1.3.1. Cooperation with the EC on drug 
precursors monitoring (L3)
n  Review of drug precursor monitoring 
(internal working document)
4.1.3.2. Initiate discussion with Eurojust on 
potential drug supply reduction indicators in the 
judiciary field (L3)
n  Session on drug supply reduction indicators 
organised during the strategic seminar on 
drug trafficking organised by Eurojust
Specific objective 4.2: Establish networks in the area of drug supply and supply reduction
Priority interventions Planned activities Expected outputs/results
4.2.1. Establish a European expert reference 
group on drug supply issues
4.2.1.1. Organise the second meeting of 
national correspondents (L1) 
n  Second meeting of national correspondents 
organised
4.2.2. Provide training for the law enforcement 
community and promote information exchange 
4.2.2.1. Provide evidence-based training on 
drug problems in Europe to senior law 
enforcement officers in cooperation with 
CEPOL (L2) 
n  Training activities delivered 
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Specific objective 4.3: Produce a strategic analysis of drug supply and supply reduction in Europe
Priority interventions Planned activities Expected outputs/results
4.3.1. Launch preparatory work for the second 
edition of the EU drug markets report 
4.3.1.1. Initiate planning of the report with 
Europol: concepts, time schedule, working 
arrangements (L2) 
n  Agreement on concept and time schedule 
with Europol
4.3.1.2. Launch collection of input from the 
Member States for analysis and drafting of the 
report (L2)
n  Collection of input launched in the Member 
States
4.3.2. Improve strategic understanding of drug 
markets 
4.3.2.1. Participate in expert forum, and review 
new grey literature and research (L2) 
n  Participation in meetings/forums
n  Internal database of reference material
n  Feasibility explored of short analysis paper 
with external partners
4.3.3. Produce joint analyses 4.3.3.1. Launch preparation of a joint 
publication with Eurojust (pending Eurojust 
approval) (L3) 
n  Data collection launched (Eurojust) and 
analysis performed 
4.3.4. Provide accessible and high-quality 
online information on drug supply issues 
4.3.4.1. Develop thematic area within context of 
the integrated website framework (L1) 
n  Updated web resources available
Specific objective 4.4: Support the Internal Security Strategy of the EU (COSI)
Priority interventions Planned activities Expected outputs/results
4.4.2. Support the EU policy cycle 
development and relevant actions 
4.4.2.1. Support the implementation of relevant 
actions of the Operational Action Plans (OAPs) 
on heroin/ cocaine trafficking and synthetic 
drugs (L2) 
n  Support provided to Europol on reporting of 
synthetic drugs production sites (see also 
activity 4.1.1.3.)
n  Support given to other areas (when defined 
by the OAPs)
WORK PROGRAMME I 2014
18 / 58
Provisions of Article 28c of the pharmacovigilance legislation 
will continue to be implemented in close cooperation with the 
European Medicines Agency. The information exchange and 
cooperation between the EMCDDA and EMA will be 
strengthened. This will include a more systematic monitoring 
of medicines under the EWS. For example, when a medicinal 
product is notified as a new psychoactive substance, a 
literature review to determine what is known about misuse, 
abuse as well as the suspected and confirmed adverse drug 
reactions is first conducted. Information will then be made 
available to EWS partners through the EDND (See Main area 
7, cross-unit project on Medicines).
Transversal work will be further developed in 2014. This will 
involve improving the monitoring of new drugs and 
establishing links with epidemiology data sources and expert 
networks. The inclusion of a new drugs component in general 
population surveys and ESPAD will be developed, and data on 
fatalities and non-fatal intoxications associated with the use 
of new drugs will be collected and analysed.
In 2014, better coordination will be established between the 
EWS and the forensic (and toxicological) laboratory networks 
in order to enhance sharing of information on the availability 
and sources of reference materials and samples of new 
psychoactive substances. The need to systematically include 
essential data sources (hospital emergency data, customs, 
etc.) at national level will be examined.
The detection and monitoring of new trends will continue to be 
implemented through the EMCDDA trendspotter methodology 
and response to these will be given through the 
multidisciplinary EMCDDA rapid response team (See Main 
area 7 – cross-unit project on new trends).
The daily workload of ‘Action on new drugs’ has increased 
substantially over the past few years, not only because of the 
growing number, type and availability of the new drugs 
reported, but also because of the high visibility and policy 
relevance of the field. This results in a high number of requests 
by institutions, Member States, researchers, etc. 
Understanding new trends and providing timely information 
on them also entails understanding complex areas and 
establishing new projects, as relevant.
The activities linked to the proposed new legislation that will 
replace the Council Decision 2005/387/JHA are subject to the 
publication/adoption of the proposed new legislative 
framework. Furthermore, some activities may be conditional 
to the EMCDDA’s legal obligations under the Decision e.g. 
requirements to undertake joint reports and requests for risk 
assessments, the number of which cannot be anticipated. The 
full EDND development is conditional upon the technical 
solutions and resources available.
I  II.5. Monitoring new trends and developments and assessing the risks of new substances
I Overview
In 2014, the EMCDDA together with its partners in the Member 
States — the Reitox network of the Early-warning system (EWS) 
correspondents — Europol and European Medicines Agency 
(EMA) will continue to ensure continuous and robust 
implementation of the EWS established under Council Decision 
2005/387/JHA. Rapid notifications and warnings on new drugs, 
forensic and toxicological analytical data, longer-term monitoring 
and analysis of health and social risks, monitoring and analysis 
of illicit and ‘legal highs’ markets, as well as description of legal 
developments, will remain key outputs of the system. 
The main working tool of the EWS, the European database on 
new drugs (EDND) will be redefined to include advanced 
technical functionalities and to reflect the provisions of the 
Commission’s new legislative framework that replaces Council 
Decision 2005/387/JHA (where appropriate). This will entail 
technological redevelopment as well as conceptual adaptation 
of all the reporting and monitoring tools and instruments 
necessary for the implementation of the information exchange 
mechanism — including the reporting forms, the EWS progress 
and final reports, the Joint Report questionnaires — in 
cooperation with Europol, as appropriate. Tools will be 
automated and interlinked and the possibility of allowing secure 
electronic submission of information into the EDND by relevant 
expert users at national level will be explored. The current 
Internet monitoring exercise will also need to be redefined and 
redesigned in order to reflect the new system, in line with the 
new database and technological advances available. 
Where requested, a risk assessment on a new psychoactive 
substance will be carried out under the auspices of the 
EMCDDA’s Scientific Committee. The operating guidelines for 
risk assessments and EWS will be adapted in line with the 
proposed new legislative framework (if appropriate). The 
EMCDDA will strive to develop a greater capacity to identify, 
assess and share information on health and, where possible, 
social implications of the wide variety of new substances now 
becoming available. 
Activities will be undertaken to increase the understanding and 
visibility of EU actions in the field of new psychoactive 
substances. The web pages related to the ‘Action on new 
drugs’ will be redesigned in order to provide customised 
information to the growing number of diverse stakeholders and 
the general public. The format and content of the EMCDDA–
Europol Annual report on the implementation of the Council 
Decision 2005/387/JHA will be redesigned and (possibly) 
launched together with the European Drug Report 2014.
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To provide a timely and sound information and analysis platform for identifying emerging trends and threats related to new 
psychoactive substances and their risks, new patterns of drug use and new developments in drug availability
Goal 2013–15
Specific objective 5.1: To ensure that the information exchange and risk assessment mechanism on new psychoactive 
substances is of high quality and implemented in a timely and efficient manner
Priority interventions Planned activities Expected outputs/results
5.1.1. Ensure the implementation of an 
Early-warning system on new psychoactive 
substances
5.1.1.1. Implement the provisions of the Council 
Decision 2005/387/JHA on the information 
exchange, risk assessment and control of new 
psychoactive substances (NPS) (L1) 
n  Timely notification of NPS to the Member 
States, EC, Europol and EMA
n  Support provided to Member States, as 
needed
n  Public health-related warnings issued
n  Ad hoc additional data collection (as required)
n  New substance profiles prepared for all 
notified substances
n  European database on new drugs (EDND) 
regularly updated
5.1.1.2. Adapt tools and processes necessary for 
the implementation of new legal and institutional 
requirements (this integrates objective 5.2 from 
the 2013–15 work programme) (L1) 
n  Reporting tools and processes adapted to 
new legal requirements
n  New draft guidelines prepared 
5.1.1.3. Maintain and strengthen the EWS 
network (L1) 
n  Annual meeting of the Reitox EWS network, 
with participation of Europol, EMA and the EC
5.1.1.4. Produce the EMCDDA–Europol Annual 
report on the implementation of the Council 
Decision 2005/387/JHA (Article 10 report) (L1) 
n  Annual report in the new format submitted 
to the EU institutions and Member States, 
and published
5.1.1. Ensure the implementation of an 
Early-warning system on new psychoactive 
substances
5.1.1.5. Dynamically appraise all EDND 
information available and launch additional data 
collection on a NPS (if appropriate) (L1) 
n  EMCDDA–Europol Joint Reports on NPS (as 
required)
5.1.1.6. Update the European database on new 
drugs to improve functionality, access and 
capacity (conditional upon the technical 
solutions and resources available) (L1) 
n  Database functionality and accessibility 
improved
n  New topic and user areas developed
n  Product-specific information available 
(project Match-it)
n  Database prepared for future requirements 
5.1.1.7. Implement multidisciplinary, 
scientifically sound risk assessment procedure 
(where requested) (L1) 
n  Studies/technical reports on the risk 
assessment prepared
n  Meeting of the Scientific Committee 
organised
n  Risk Assessment Report submitted to the 
Commission and the Council
n  Report on the risk assessment published 
5.1.1.8. Increase the understanding of NPS 
phenomenon and the visibility of EU actions in 
this area (L1) 
n  Thematic web pages (Action on new drugs) 
revised within the context of the new 
integrated EMCDDA website framework
n  Participation in relevant international and 
European forums, the feasibility of (co-)
organising the 4th International 
multidisciplinary forum on new drugs and 
the 3rd International conference of novel 
psychoactive substances explored
5.1.1.9. Maintain the EMCDDA’s online drug 
profiles series (L3) 
n  All drug profiles consolidated and updated 
(as required)
5.1.2. Implement the provisions of Article 28c 
of the EU Pharmacovigilance (PhV) legislation
5.1.2.1. Implement the provisions of Article 28c of 
the EU Pharmacovigilance (PhV) legislation (L1) 
n  Information exchanged with EMA and the EU 
PhV system
5.1.3. Support capacity development in the 
forensic science and toxicology area 
5.1.3.1. Support the formation of an informal 
forensic science and toxicology network (in line 
with OAP for 2012–13 of the new policy cycle 
within COSI) (see also priority intervention 4.2.1) 
(L2) 
n  Informal network of selected forensic, 
toxicology and law enforcement experts 
supported
n  Cooperation between the EMCDDA and the 
European Network of Forensic Science 
Institutes (ENFSI) strengthened
5.1.4. Consolidate and improve the 
methodology for monitoring the Internet
5.1.4.1. Snapshot exercises conducted and 
methodology reviewed and updated (L2) 
n  Automated tools for monitoring the Internet 
evaluated
n  Methodology for monitoring the Internet 
reviewed
n  Internet snapshots conducted 
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Specific objective 5.2: Facilitate the development of early responses to potential threats by strengthening the systems for 
identifying, tracking and understanding new and emerging trends in drug use, availability and adverse consequences
Priority interventions Planned activities Expected outputs/results
5.2.1. Improve monitoring of new drugs and 
links with epidemiology data sources and 
expert networks 
5.2.1.1. Carry out an analysis of fatalities 
associated with the use of NPS, based on 
existing and newly collected data (L2) 
n  Pilot tool to monitor fatalities associated with 
new psychoactive substances integrated 
into the EDND and used for relevant new 
psychoactive substances
5.2.1.2. Conduct a review on the monitoring of 
fatal and non-fatal intoxications associated with 
NPS and the inclusion of poison control centres 
and hospital emergency rooms (L3) 
n  Follow-up on conceptual paper developed in 
2013, including piloting the use of selected 
key sentinel poison control centres for 
monitoring non-fatal intoxications 
associated with NPS, as appropriate
5.2.1.3. Revise and amend the health 
consequences sections of existing EMCDDA 
drug profiles (L3) 
n  Relevant drug profiles updated on health 
consequences 
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I  II.6. Improving Europe’s capacity to monitor and evaluate policies
I Overview
In 2014, responding to the EU action plan on drugs (2013–16) 
overarching indicator number 14, work in this area will 
continue to monitor developments in legislation, national drug 
strategies, coordination mechanisms and public expenditure 
estimates in EU Member States. Over the next year, this will 
involve taking stock of current knowledge on drug policy and 
exploring different policy models.
Monitoring of drug policies will be advanced through an 
analysis of the presence and role of drug policies at the local 
level. Work in this area will also focus on supply reduction 
policies, while the publication of a composite index of drug 
legislation will allow a first view towards objective taxonomies. 
Responding to the need for public policies to be more cost 
efficient, analysis will begin on the concept of value for money 
in the treatment area, while the effects of the economic 
recession will continue to be followed closely. There will also 
be historical reviews of national drug policies in Poland and 
Austria, furthering our understanding of the diversity of 
national approaches in Europe.
Network building in this area will include the annual meeting 
of legal and policy correspondents and there will be continued 
improvement of the EMCDDA’s online presence in this area. 
We will continue to provide Member States with support to 
their evaluation of drug policies on request.
Improve the understanding of European and global policy developments by providing relevant and timely drug policy data, 
analysis and expertise
Goal 2013–15
Specific objective 6.1: Develop European and global drug policy monitoring and analysis
Priority interventions Planned activities Expected outputs/results
6.1.2. Increase awareness of national and EU 
level policy developments 
6.1.2.1. Finalise study on drug trafficking 
penalties (L2)
n  EMCDDA Paper: Comparative analysis of 
trafficking penalties 
6.1.2.2. Review case studies of policy at the EU, 
national and local level (L2)
n  EMCDDA Papers:
–  National policy profile
–  Supply and external security: an EU 
overview
–  Drug policies of large cities
–  Evolution of drug strategy in the EU (draft 
paper) 
6.1.4. Monitor economic issues relevant to 
drug policy 
6.1.4.1. Finalise analysis of developments in 
drug-related public expenditure (L2) 
n  Literature review and case studies 
conducted
6.1.4.2. Scope options for economic analysis in 
the area of drug treatment (L3)
n  Internal working document on options and 
utility of macro and micro level economic 
analysis and review in the area of drug 
treatment
6.1.5. Support the EU drug strategy and action 
plan(s)
6.1.5.1. Provide technical input to the EU in the 
follow-up and evaluation of its drug strategy and 
action plans (L2) 
n  Data and expertise provided for relevant 
areas of the action plans (within available 
resources)
n  Technical input to meetings (on request)
6.1.6. Support Member States in developing 
and evaluating their national drug policies 
6.1.6.1. Provide information available on: 
evaluation approaches, methods to estimate 
public expenditure and legal developments (on 
request) (L2) 
n  Technical support provided on request 
(resource dependent) 
6.1.7. Provide online resources on drug policy 6.1.7.1. Maintain and revise the European legal 
database on drugs (ELDD) (L1) 
n  Web resources updated and revised
6.1.7.2. Update web content for national drugs 
strategies and improve format (L1) 
n  Web resources updated and improved
6.1.7.3. Revise online resources in the area of 
drug-related public expenditure (L1) 
n  Web resources revised
Specific objective 6.2: Strengthen European networks in drug law and drug policy analysis
Priority interventions Planned activities Expected outputs/results
6.2.1. Maintain network of legal and policy 
correspondents
6.2.1.1. Organise the legal and policy 
correspondents’ meeting (including thematic 
session on new psychoactive substances) (L1) 
n  Meeting report and thematic analysis
n  Access channel to national level expertise 
available
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I  II.7. Scientific coordination, research and content support
I Overview
The scientific work of the EMCDDA covers a wide range of 
complex topics that require detailed knowledge and 
specialised expertise. An ongoing commitment to improving 
the scientific quality of our work is a prerequisite to fulfilling 
our role as a centre of excellence for the collection, analysis, 
and dissemination of drug-related information. It is therefore a 
primary objective for scientific management and coordination.
In 2014, we will agree on a protocol for developing EMCDDA 
guidelines and handling requests for scientific advice. The 
main output of this work will be a declaration of methods 
adopted by the EMCDDA to ensure that the best and most 
systematic approach is used when EMCDDA guidelines are 
developed and/or recommendations in the drug addiction 
field are made.
The EMCDDA will continue its collaboration with the EU 
Agencies Network of Scientific Advisors (EU ANSA) in order to 
further improve the quality of the agency’s scientific work. In 
2014, the EU ANSA network will place greater emphasis on 
dealing with uncertainties in scientific advice and peer review 
scientific quality activities.
Dissemination of information is at the core of the EMCDDA’s 
functioning. Providing training is one way of informing experts 
at different levels on the agency’s findings and results. In 
2014, the EMCDDA will continue its work on the development 
of an integrated training strategy, building on the experiences 
acquired from academic training activities, capacity building 
projects and other initiatives. E-learning and web-based 
training are also important elements in future knowledge 
translation activities. A key priority in 2014 will be the 
improved quality and coherence of the EMCDDA’s information 
collection and reporting system. Given that the data collection 
capacity at national level is limited, ongoing review of existing 
data demands and careful scrutiny of new requests are 
needed. A data coherence group will be set up in consultation 
with the focal points to ensure that demands upon the system 
do not exceed capacity.
The central challenge for the EMCDDA is to continue to deliver 
high-quality scientific work. In 2014 the EMCDDA’s Editorial 
board and product management system will continue to 
support an integrated approach to output generation whereby 
scientific and communication issues are brought together, 
processes assured and quality control maintained. The overall 
quality control framework for scientific publications will be 
formalised and implemented in 2014, setting out the 
procedures for internal coordination, quality control processes 
as well as peer-review mechanisms for products. External 
support is required to increase our capacities in delivering 
high-quality scientific work. In particular it is needed to 
provide support for the scientific writing of EMCDDA 
publications and a group of external peer reviewers, in close 
collaboration with the EMCDDA´s Scientific Committee, will 
assess and improve the quality of our publications.
Transversal activities continue to be supported structurally by 
the cross-unit projects (CUPs) created in 2013: CUP 
Medicines (in the context of polydrug use), CUP Quality 
assurance, CUP New trends and CUP Treatment. CUPs are 
timebound, formal structures tasked with completing 
important transversal tasks.
In compliance with the EMCDDA’s mandate, the feasibility of 
implementing a new conceptual framework for monitoring the 
misuse of medicines will be conducted within the CUP 
Medicines. Initial activities will focus on the misuse of 
psychoactive medicines used in drug treatment, trends in 
polydrug use and effective and efficient information exchange. 
Data on the misuse of medicines and substances with 
medicinal properties will be better integrated in EMCDDA 
reporting. The Quality assurance CUP will continue the 
consensus-building exercise initiated in 2013 around a 
top-level model for data quality assurance management and 
will define the implementations steps and follow-up 
mechanisms for quality assurance initiatives considered as 
priority in 2013. Key initiatives planned by the CUP New trends 
are the development of a new trends discussion forum, a 
review of data sources to improve timeliness and 
sensitiveness and the publication of a new trendspotter case 
study. The activities reflect an increasing recognition of the 
importance of facilitating the development of early responses 
to potential threats by strengthening the systems for 
identifying, tracking and understanding new and emerging 
trends in drug use, availability and adverse consequences.
An active link with the scientific world outside the EMCDDA 
will be kept through many activities and collaboration with 
ALICE-RAP (1), European Research Area Network on Illicit 
Drugs (ERANID) (2), EUFAS (European Federation of Addiction 
Societies), ISAJE (International Society of Addiction Journal 
Editors) and others will be continued. Publications of EMCDDA 
staff members in scientific journals are another important tool 
to inform science and research on EMCDDA results.
(1) ALICE RAP — Addiction and Lifestyles in Contemporary Europe Reframing 
Addictions is a 5-year research project funded through the Socio-economic 
Sciences and Humanities (SSH) Theme of the Seventh Framework Programme 
for Research and Development (FP7): http://www.alicerap.eu/
(2) ERANID — European Research Area Network on Illicit Drugs is an ERA-NET 
project funded through the SSH Theme of FP7: http://www.eranid.eu/
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To produce high-quality scientific work through efficient working practices
Goal 2013–15
Specific objective 7.1: Ensure the coordination of scientific activities so that resources are efficiently used, objectives are 
achieved and quality control of outputs is maintained
Priority interventions Planned activities Expected outputs/results
7.1.1. Improve handling of requests for 
scientific advice and opinion
7.1.1.1. Finalise concepts paper on procedure 
for handling requests for scientific advice (L3) 
n  Guidelines prepared 
7.1.2. Develop EMCDDA strategy on training 
for external audiences and coordinate training 
activities 
7.1.2.1. Organise the 2014 Summer school, 
‘Drugs in Europe: supply, demand and public 
policies’ (L2) 
n  2014 Summer school organised and training 
material available 
7.1.2.2. Finalise options paper on integrated 
training strategy (including academic training) 
(L3) 
n  Integrated training strategy endorsed 
internally
7.1.2.3. Collaborate with EU and academic 
training initiatives (where appropriate and within 
resources) (L3) 
n  EMCDDA contribution to European Master in 
Drug and Alcohol Studies (EMDAS), 
European Society for Prevention Research 
(EUSPR), Initial Training Network (ITN-
SEWPROF), etc.
7.1.3. Support the production of high-quality 
scientific content
7.1.3.1. Coordinate scientific activities to ensure 
that resources are managed efficiently, that 
objectives are achieved and that quality control 
of outputs is assured (L1) 
n  Scientific coordination meetings, scientific 
division meetings and scientific unit 
meetings organised and internal 
communication tools maintained
n  Improved coordination and planning of 
outputs (products database) 
7.1.3.2. Implement the EMCDDA overall quality 
control framework for scientific publications (L1)
n  Scientific content of key EMCDDA 
publications checked and quality controlled
n  Support provided for content production 
(pre-editing), and provision of scientific 
writing for EMCDDA publications
n  External scientific writing support 
established and operational
n  Peer-review system implemented (in 
consultation with Scientific Committee): 
guidelines for peer review finalised and key 
publications peer reviewed
7.1.3.3. Scientific reputation maintained by 
publication in high-impact scientific journals (L2) 
n  Small number of articles published in 
high-impact scientific journals 
7.1.3.4. Disseminate key results and technically 
support European debate on drug issues (L2) 
n  Presentations and technical contribution 
delivered at relevant scientific and 
institutional meetings (resources dependent)
7.1.4. Coordinate internal information 
exchange on new developmental areas and/or 
transversal projects
7.1.4.1. Ensure the coherence of the overall 
reporting system, ensure efficiency of data 
collection requests and adjust requirements in 
context of changes in resource availability and 
institutional needs (L1) 
n  Follow-up action plan for systemic review of 
tools implemented
n  Mechanism(s) for coherence, oversight and 
quality control established (Data coherence 
group)
n  Revised national reporting package agreed 
with focal points
7.1.4.2. CUP Quality assurance: develop a 
model and implementation strategy for data 
quality assurance management (L2) 
n  Framework document drafted
n  Internal coordination mechanism 
established
7.1.4.3. CUP New trends: coordination group to 
improve awareness on new developments and 
timeliness of reporting (L2) 
n  Online discussion forum developed and 
operational conceptual framework 
developed (Data review completed and 
recommendations developed)
n  Rapid assessment and response (RAR) on 
key issue(s) conducted, including trendspotter 
study and ad hoc rapid assessments
7.1.4.4. CUP Treatment: internal coordination to 
ensure coherence and dialogue across 
treatment area (L2) 
n  Improved communication channels and 
integrated outputs 
7.1.4.5. CUP Medicines (in the context of 
polydrug use): develop conceptual framework, 
thematic web resources and develop expertise 
(L2) 
n  Conceptual framework including options for 
monitoring drafted
n  Thematic web page developed
n  Database of articles and grey literature 
established
WORK PROGRAMME I 2014
24 / 58
Specific objective 7.2: Support drug-related research, audit key developments and promote the use of research findings
Priority interventions Planned activities Expected outputs/results
7.2.1. Monitor and disseminate developments 
in drugs research
7.2.1.1. Update and improve public website and 
intranet research page (L1) 
n  Updated research area on public website 
and intranet
n  Input provided to Reitox Research Forum
7.2.1.2. Update research country profiles within 
context of integrated website framework (L1) 
n  Updated web-based profiles available
7.2.2. Support the development of the EC 
research agenda
7.2.2.1. Provide input on research priorities at 
EU and Member State level (L2) 
n  Report submitted to the Horizontal Drugs 
Group (HDG) for the Annual Dialogue on 
Research (in collaboration with the Scientific 
Committee)
n  Support provided to national initiatives (on 
request) 
7.2.2.2. Support the European Research Area 
Network on Illicit Drugs (ERANID) (L3) 
n  EMCDDA input to ERANID provided
7.2.3. Further develop collaboration with the 
scientific community through dissemination of 
findings and increased contribution to relevant 
events
7.2.3.1. Promote dissemination of significant 
research findings (L2) 
n  Improved awareness of significant research 
findings
7.2.3.2. Increase collaboration with projects 
and initiatives developed by the scientific 
community (L2) 
n  Increased input, visibility and standing of 
EMCDDA outputs
n  EMCDDA participation and input provided to 
relevant scientific meetings (resource 
dependent)
n  Participation in EU ANSA 
25 / 58
I  II.8. Cooperation and collaboration with key partners
I Overview
Cooperation with key external partners, namely with EU 
institutions and bodies, national policymaking bodies, 
international organisations, civil society and third countries, is 
a cornerstone of the agency’s mandate. This represents an 
important part of the EMCDDA’s work within the current 
three-year strategy and work programme which commits the 
agency to strengthening and enhancing cooperation with 
European, national and international partners.
Our work with key external partners is implemented in 
different areas and on various levels — institutional 
cooperation versus content-related and core business-
oriented activities.  
 
At the institutional level, maintaining close cooperation and 
collaboration with the EU institutions, namely the European 
Parliament (EP), the Council of the EU and the European 
Commission (EC), remains one of our main priorities. The 
agency will further consolidate its role as technical 
information provider at institutional meetings in the field of 
drugs, such as the Horizontal Drugs Group (HDG), the EU 
policy dialogues, the National Drug Coordinators (NDC) and 
the Standing Committee on Internal Security of the European 
Union (COSI). As in previous years, the agency’s European 
Drug Report will be presented to EU institutions. Regarding 
the EC, coordination will be ensured through meetings and 
regular contacts with the parent Directorate-General (DG) and 
content-related DGs. Furthermore, the EMCDDA will continue 
to provide technical advice and support the transfer of 
knowledge to the EC for the planning, execution and 
dissemination of information related to EC-funded drug-
related projects (e.g. COPOLAD and CADAP).
The EU action plan on drugs (2013–16) was adopted in June 
2013. The EMCDDA is defined as reporting agency for 23 
actions and as actors in 15 cases. The implementation of the 
activities that will take place in 2014 will be reported in the 
European Commission biennial progress report.
Cooperation and collaboration with  
key partners
Also at the institutional level, the EMCDDA will further 
strengthen cooperation with other EU agencies in order to 
define and implement common positions, policies and working 
methods and tools. This will include participation in and 
contribution to the Heads of Agencies and interagency 
technical and coordination networks and clusters, to ensure 
synergies and promote a common EU approach.
At technical level, work in 2014 will be based on the already 
existing working arrangements and cooperation agreements 
and the activities and projects initiated in 2013 will be 
continued. In this respect the close collaboration with Europol, 
EMA, ECDC, Eurojust and CEPOL will be further strengthened. 
At the same time, within the available resources, the EMCDDA 
will continue to be responsive to the ad hoc requests for 
collaboration coming from established partners throughout 
the year. The agency remains open to new areas and 
arrangements for cooperation, provided that these are clearly 
in line with the EMCDDA´s international cooperation strategy, 
the internal planning/priorities and the available resources.
At the international level, cooperation with some key partners 
will be maintained or further explored in particular with the UN 
bodies (UNODC, WHO, UNAIDS), with the Pompidou Group 
and CICAD, and specifically on the supply side with the WCO 
and Interpol.
With regard to cooperation with non-EU countries, in line with 
its mandate and consistent with the EMCDDA strategy for 
international cooperation, the EMCDDA’s work is structured 
around three groups of countries: candidate and potential 
candidate countries to the EU (3), the European 
Neighbourhood Policy (ENP) countries (4) and other third 
countries. Most of these activities are being developed in the 
context of EC-funded technical cooperation projects, such as 
the Instrument for Pre-Accession Assistance (IPA), or with the 
(3)  As of 1 September 2013, Candidate countries are: Former Yugoslav Republic 
of Macedonia, Montenegro, Serbia and Turkey. Potential candidate countries: 
Albania, Bosnia and Herzegovina, Kosovo (This designation is without 
prejudice to positions on status, and is in line with UNSCR 1244 and the ICJ 
Opinion on the Kosovo declaration of independence).
(4)  Algeria, Armenia, Azerbaijan, Belarus, Egypt, Georgia, Israel, Jordan, Lebanon, 
Libya, Moldova, Morocco, Occupied Palestinian Territory, Syria, Tunisia and 
Ukraine.
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ENP countries (Armenia, Azerbaijan, Georgia, Israel, Moldova, 
Morocco and Ukraine) aiming at strengthening the capacity of 
ENP partner countries to react to new challenges and 
developments on the drugs situation, 3) limited technical 
support and expertise to EC programmes such as COPOLAD 
and CADAP 6.
financial support of EC programmes such as the Technical 
Assistance and Information Exchange instrument (TAIEX).
For 2014, the main activities in order of priority are: 1) 
successful completion of the IPA 4 project which started in 
2012, 2) implementation of a new EC-funded project with the 
To support EU drug policy debate and effective actions and increased capacity for reporting on drug use in non-EU countries 
with an emphasis on countries which represent a priority for EU action in the drugs area
Goal 2013–15
Specific objective 8.1: Coordinate, cooperate and provide technical support at the EU level
Priority interventions Planned activities Expected outputs/results
8.1.1. Provide technical support to EU policy 
dialogue and deliberations
8.1.1.1. Provide expertise and technical 
information to the European Commission, 
Council and Parliament (L1)
n  Support for the European Commission, 
Council and Parliament provided (as 
requested)
n  2014 European Drug Report presented to EU 
institutions 
8.1.1.2. Contribution to the implementation of 
the EU drugs strategy (2013–20) and the action 
plan (2013–16) as required (L1)
n  Follow-up of EMCDDA indicated actions and 
reporting obligations
8.1.1.3. Consolidate the EMCDDA’s role of 
technical information provider in institutional 
drugs meetings (L2)
n  EMCDDA technical backstopping and 
support to policy debate at HDG and in other 
appropriate forums (as requested)
8.1.1.4. Provide support for the implementation 
and/or monitoring of other policy documents 
and initiatives in health and justice and home 
affairs areas (as requested) (L2)
n  Technical reports, reviews, attendance to 
meetings and presentations, etc. (as 
requested)
8.1.2. Provide ad hoc technical and scientific 
support to EC regional programmes
8.1.2.1. Provide input for the EC regional 
projects (in line with the EMCDDA mandate and 
priorities in area of international cooperation, 
subject to resources) (L2)
n  EMCDDA is represented in the COPOLAD 
and CADAP six steering committees
n  Scientific and technical support provided to 
COPOLAD, CADAP, etc. 
8.1.3. Ensure effective collaboration with other 
EU agencies
8.1.3.1. Cooperate with EU agencies, in order to 
define and/or implement common positions, 
policies and working methods and tools (L2)
n  Participation in the Heads of Agencies 
meetings, in interagency networks, and in 
JHA agencies cluster 
8.1.3.2. Implement Memoranda of 
understanding (MoUs) and other working 
arrangements in force with Europol, CEPOL, 
Eurojust, ECDC, EMA (L2)
n  Work programmes and cooperation 
agreements endorsed and implemented
Specific objective 8.2: Improve dialogue with policy audience, civil society and relevant technical and scientific bodies
Priority interventions Planned activities Expected outputs/results
8.2.1. Monitor key developments and improve 
information exchange with civil society 
partners
8.2.1.1. Engage in dialogue with civil society 
organisations operating in the field covered by 
the EMCDDA mandate (L3)
n  Participation in the EU Civil society forum on 
drugs and HIV/AIDS
n  Dissemination of the EMCDDA’s expertise, 
findings and products
8.2.2. Improve understanding of information 
needs and identify effective communication 
channels with national policy bodies
8.2.2.1. Further strengthen relations with the 
EMCDDA Member States and in particular with 
the key national policymaking bodies, and the 
Portuguese authorities (L2)
n  Specific action to be defined in close 
collaboration with the focal points as part of 
the Reitox development strategy (see also 
10.5.2.2.)
n  Collaboration with the hosting country 
authorities, namely with the Parliament, 
Government and Presidency of the Republic
8.2.3. Information exchange and identify 
synergies with appropriate technical and 
scientific bodies working in the drugs field
8.2.3.1. Conduct bilateral exchanges and 
explore opportunities for collaboration with 
scientific bodies (resources dependent) (L3)
n  Improved dissemination and awareness 
raising of EMCDDA activities 
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Specific objective 8.3: Coordinate, cooperate and provide appropriate technical input to work conducted by international bodies 
in the drugs field (5)
Priority interventions Planned activities Expected outputs/results
8.3.1. Provide technical input and information 
to international activities (in line with mandate 
and strategy) 
8.3.1.1. Contribute to reports, expert meetings, 
international projects, trainings and seminars 
and exchange information with international 
partners and regional bodies (L3)
n  Input to reports, meetings, projects, training 
activities and seminars
n  Strengthened cooperation with main external 
partners in technical cooperation projects
8.3.2. Support the development of coherent 
information standards and information 
resources at international level 
8.3.2.1. Cooperate with major European and 
global partners to increase quality, 
comparability and coherence of data in 
international reporting (L3)
n  Contribution to expert groups on quality 
issues, to data validation exercises and to 
codes harmonisation where possible 
8.3.3. Develop and implement joint work with 
key external partners
8.3.3.1. Implement existing arrangements and 
work programmes (L2)
n  Joint work in the core scientific areas of 
EMCDDA work with international partners 
ensured and implemented
Specific objective 8.4: To support capacity development and enhance the scientific value of drug monitoring activities within 
candidate (CC) and potential candidate countries (PCC)
Priority interventions Planned activities Expected outputs/results
8.4.1. Consolidate institutionalisation of 
national focal points within CC and PCC
8.4.1.1. Perform IPA 4 project coordination 
activities and provide technical and 
administrative support for implementation of 
IPA 4 project-related national activities in CC 
and PCC (L1)
n  Level of achievement of the project expected 
results. Target for 2014: 80 % expected 
results achieved
n  Budget execution rate (commitment 
appropriations). Target for 2014: minimum 
95 %
n  Project activity reports
8.4.1.2. Prepare IPA 5 technical proposal 
(depending on the EC decision on new IPA 
programme for agencies) (L2)
n  IPA 5 project technical proposal prepared 
and sent to the relevant EC services
8.4.2. Foster scientific cooperation in relation 
to data collection, interpretation and analysis 
and accrue added value from cooperation 
activities
8.4.2.1. Enhance participation of CC and PCC in 
EMCDDA work and support CC and PCC in 
producing new information on drugs in their 
countries and disseminating the data (L2)
n  Reitox Academies organised at regional and 
national level
n  Data collection increasingly aligned with EU 
standards and better analysis of available 
data
8.4.2.2. Provide EC services with regular 
information on the progress made by countries 
(L2)
n  EC progress reports on CC and PCC 
informed by EMCDDA IPA 4 activities 
8.4.2.3. Prepare a first set of products 
presenting the drugs situation in the Balkan 
region (L3)
n  Set of products defined and first products 
finalised and launched (IPA 4) 
(5) In particular UNODC, WHO UNAIDS, Pompidou Group and CICAD, Interpol and WCO.
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Specific objective 8.5: Support capacity development, information availability and exchange with interested ENP and other 
non-EU countries
Priority interventions Planned activities Expected outputs/results
8.5.1. Launch the EMCDDA technical 
cooperation with interested ENP partner 
countries and Russia to improve knowledge 
base
8.5.1.1. Perform ENP project coordination and 
implementation activities (L1)
n  Effective implementation of project 
activities, measured by the budget execution 
rate (commitment appropriations), target 
2014: minimum 80 %
n  ENP project reports
n  Training provided
n  Country overviews for the seven 
participating countries prepared or updated 
on the EMCDDA website
8.5.1.2. Provide EC services with regular 
information on the progress made by countries, 
and on obstacles to project’s implementation 
(L2)
n  EC progress reports on ENP countries 
informed by EMCDDA project activities 
8.5.1.3. Strengthen the institutional relations 
and working arrangements with ENP countries 
(L2)
n  MoU with Armenia signed by both parties
n  Working programmes/frameworks for 
cooperation adopted/updated
8.5.1.4. Promote the work in the area of 
international cooperation, in particular 
cooperation with ENP countries, and 
developments in international issues (L3)
n  Concept for a new product on international 
issues developed 
8.5.2. Exchange information, working 
practices and methodology on the 
identification of new psychoactive substances 
with other interested regional and national 
monitoring systems 
8.5.2.1. Capacity building and information 
exchange on new psychoactive substances 
with ENP countries (L2)
n  Internet snapshot exercise conducted
n  Participation of ENP experts in EWS annual 
meeting
n  Meeting on drug control options for NPS
8.5.2.2. Extend functionality of EDND to 
disseminate appropriate information to ENP 
countries (L2)
n  EDND communication functionality 
extended and ready to be implemented
8.5.3. Support technical capacity 
development for drug monitoring systems 
8.5.3.1. Prepare training materials (Handbook II) 
and guidelines based on the European model to 
support capacity development work (L2)
n  Handbook II concept developed 
8.5.4. Promote EU model for NDOs and 
National Drug Information Systems
8.5.5.1. Organise third Reitox week with 
participation of EMCDDA Member States, CC 
and PCC, ENP countries and Russia (L2)
n  Extended Reitox network meets once per 
year and contributes to the improvement of 
data collection in partner countries
8.5.5.2. Disseminate EMCDDA knowledge in 
third countries (L3)
n  Presentations and technical contribution 
delivered at conferences and events (based 
on resources)
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information in Europe. Following on from the content review 
carried out in 2013, key content will be overhauled in 2014. 
Working in a web-focused environment implies a shift in 
language, style and technique. The communication team will 
work closely with colleagues responsible for developing 
content to help achieve the best quality of communication 
possible across channels and languages. An improved quality 
assurance system will be introduced to ensure that quality 
checks for data and language are as rigorous as for other 
EMCDDA outputs. We will begin the migration of web content 
into the new content management tool. We will also establish 
the internal guidelines and workflows to ensure a smooth flow 
of updated content. With the help of the new content 
management tool, we will develop a more dynamic and better 
interlinked website.
Keeping abreast of the needs of our customers requires a 
regular review of how we are serving them and by what 
means. The utility of the existing EMCDDA product types was 
analysed under the systemic review and some new tools and 
channels to convey results were identified in the 2013–15 
work programme. In 2014, we will continue to adapt the 
EMCDDA product range in line with these findings and 
complete the implementation of the brand refresh that 
commenced in 2013.
Following the detailed mapping exercise of our stakeholders 
and target audiences carried out in collaboration with the 
scientific units in 2013, we will draw up an audience 
engagement strategy to be implemented in the coming years.
Media interest in EMCDDA results continues to grow. In 2014, 
we will develop our ‘heads up’ approach (advance warning) so 
the media can plan the coverage of our work better. We will 
also develop our provision of audiovisual materials.
The EMCDDA’s linguistic policy is based on a thorough 
assessment of need, privileging quality over quantity. 
Guidelines and instruments will be developed to assist in 
making sound financial decisions that achieve maximum 
impact and the increasing number of requests to translate 
EMCDDA outputs at national level will be better documented. 
We will collaborate with existing EU project networks who 
serve as multipliers for producing language outputs.
I  II.9. Communicating the EMCDDA’s findings to external audiences
I Overview
Communication is a core activity of the EMCDDA both in 
supporting its role as an information agency and in helping 
further its reputation as the ‘reference point on drugs in 
Europe’. The integrated communication strategy, adopted in 
2012, sets out the fundamental principles for communicating 
our knowledge and presents the tools available to build and 
nurture relations with our stakeholders, target audiences and 
partners. An action plan, developed during 2013, details the 
follow-up work needed to implement the strategy. Activities in 
2014 will be guided by this strategy and its action plan which 
aim to ensure that communication activities are not an 
isolated function at project-end, but an integral part of the 
agency’s scientific and technical activity. At a time of 
heightened need for an efficient use of resources, this 
integrated and multidisciplinary approach pools scientific and 
technical expertise to produce pertinent and cost-efficient 
results.
Applying the integrated approach espoused by the new 
communication strategy requires significant changes to the 
way we work. In 2014, we will continue to develop the 
practices and workflows with the scientific units to enable the 
end product and its appropriate communication channel to be 
identified upstream.
The release of the European Drug Report package comprising 
the Trends and developments report, Perspectives on drugs, 
Statistical bulletin and Country overviews — planned for the 
end of May 2014 —demonstrates the agency’s continued 
commitment to improving the timeliness of its reporting. Work 
processes will be refined to meet this deadline with all the 
necessary quality controls undertaken. Work will commence 
on redeveloping the Statistical bulletin with an increased level 
of interactivity. We will continue to make our results more 
accessible through data visualisations and audiovisual 
material, and across a variety of communication platforms.
The EMCDDA website is the agency’s primary means of 
communicating across all target audiences and is the key to 
reinforcing the agency’s profile as the primary source of drug 
Supporting the achievement of results
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further rationalise participation in external events, in line with 
the existing resources and priorities. The role of staff as 
ambassadors will be further developed via training and 
coaching in representation.
We will continue to provide reliable and efficient information, 
library and documentation services supporting the research 
needs of the scientific staff. We will use internal 
communication activities to support and develop the cross-
unit collaboration that needs to take place for the 
communication strategy to be successful.
The channels at our disposal to promote EMCDDA work 
results include the web, publications and print products, 
events and conferences, media relations, audiovisual material 
and social media. These multiple, and often converging, 
information channels demand strong synergies between the 
different specialities in the communication team. Such 
cross-functional working allows the agency to shape and 
repurpose content efficiently and mobilise a mix of options, 
with the ultimate goal of maximising the impact for the 
customer. Exploring new dissemination options and tools is 
part of our commitment to efficiency, which requires us to 
EMCDDA information and analyses of high quality reach their intended audience in a timely and cost-efficient manner
Goal 2013–15
Specific objective 9.1: Implement the integrated communication strategy and action plan
Priority interventions Planned activities Expected outputs/results
9.1.1. Develop procedures to integrate 
communication perspective at product 
conception
9.1.1.1. Define practices and workflows with 
scientific units to ensure integrated approach to 
product conception (L2)
n  Improved planning and shaping of products 
upstream (see also priority intervention 
9.2.1) 
9.1.1.2. Improve scheduling of outputs (L2) n  Better-paced and better-targeted launches
9.1.2. Redesign product range to reflect new 
EMCDDA strategy and work programme 
(brand refresh)
9.1.2.1. Adapt product range to reflect systemic 
review findings and commitments set out in 
2013–15 work programme (L2)
n  A rationalised and balanced products mix 
with cost savings and efficiency gains
9.1.2.2. Conclude work on brand refresh 
including redesign of publications (titles and 
series) (L2)
n  Refreshed corporate identity for EMCDDA 
products 
9.1.3. Implement revised linguistic policy 9.1.3.1. Apply new translation policy to 
EMCDDA products (L2)
n  Procedures, guidelines and instruments 
developed to support translation 
management 
9.1.3.2. Conduct needs assessment to select 
products that represent good value for 
translation (L2)
n  More strategic choices made to achieve 
maximum impact (taking into account new 
language groups, in line with the activities in 
the area of international cooperation — see 
also Main area 8)
9.1.3.3. Continue to work with national focal 
points on the terminology/glossary project (L2)
n  New terms with agreed and translated 
definitions uploaded to IATE (the EU’s 
multilingual term base)
9.1.5. Engaging better with audiences 9.1.5.1. Develop an audience engagement 
strategy (based on mapping exercise 
completed in 2013) (L2)
n  Audience engagement strategy 
9.1.6. Monitor and evaluate the impact of 
communication activities
9.1.6.1. Continue routine work in the areas of 
dialogue and evaluation and begin to define 
indicators (L2)
n  Better knowledge of outreach and impact 
gained in order to inform future EMCDDA 
strategies
n  Performance indicators defined to allow 
better measuring of the impact of 
communication activities
9.1.7. Implement the internal communication 
strategy and action plan
9.1.7.1. Map and analyse procedures for 
communicating on specific content areas (L3)
n  Action plan and procedures implemented
9.1.7.2. Improve and develop internal 
communication channels (L3)
n  Improved knowledge-sharing tools available
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Specific objective 9.2: Publish high-quality and timely products in line with targets committed to in the 2013–15 work 
programme
Priority interventions Planned activities Expected outputs/results
9.2.1. Assure publication, launch and 
dissemination of EMCDDA products
9.2.1.1. Deliver timely editing, production, 
dissemination and promotion services (L2)
n  Planned products published, launched and 
disseminated (see list of outputs)
n  Monthly Editorial board meetings held to 
prioritise products
n  Monthly follow-up on products meetings held 
to plan resources and monitor production
9.2.1.2. Improve quality control in the 
production process of EMCDDA products (L2)
n  Clear procedures and workflows for content 
production and publication in place 
9.2.2. Produce the European Drug Report 
package 
9.2.2.1. Fine tune the European Drug Report 
package based on feedback from 2013 (L1)
n  Improved, streamlined and electronically 
integrated European Drug Report package 
9.2.2.2. Draft, edit and produce the European 
Drug Report: Trends and developments (L1)
n  Report successfully produced and launched
9.2.2.3. Conceive and develop new set of PODs 
(Perspectives on drugs) with interactive 
features and update existing ones (L1)
n  New and updated set of PODs online 
showcasing topical content 
9.2.2.4. Review the presentation of the 
Statistical bulletin (see also Main area 1) (L1)
n  More accessible and interactive Statistical 
bulletin
9.2.2.5. Prepare Country overviews in 
consultation with NFPs (L1)
n  30 Country overviews published online, as 
part of the European Drug Report package 
Specific objective 9.3: Increase the relevance and impact of the EMCDDA’s online presence
Priority interventions Planned activities Expected outputs/results
9.3.1. Develop web content in line with 
integrated communication strategy 
9.3.1.1. Work with scientific units to develop 
integrated web resources (see main areas 1–6 
for details) (L1)
n  Web resources revised for each area within a 
common structure and approach 
9.3.2. Increase interactivity and targeted 
approach of the website
9.3.2.1. Continue to develop interactive 
products and improve findability of information 
(L1) 
n  Increased number of interactive products 
launched
n  More possibilities for users to interact with 
information 
9.3.3. Introduce new quality assurance system 
for web content
9.3.3.1. Implement web governance strategy 
(L1)
n  Improved governance of EMCDDA web 
resources 
9.3.3.2. Implement new quality assurance 
measures (L2)
n  Improved workflows for content sign-off, 
ensuring consistent approach for publishing 
content
n  Quality threshold for various categories of 
information defined
9.3.4. Implement new content management 
tool and migrate content 
9.3.4.1. Tailor new content management tool to 
defined needs and migrate relevant content (L1) 
n  Efficient and flexible tool that better meets 
agency’s needs
n  Relevant content migrated
Specific objective 9.4: Enhance the EMCDDA’s reputation and recognition as the European central reference point for drugs 
information
Priority interventions Planned activities Expected outputs/results
9.4.2. Ensuring visibility of EMCDDA across 
multiple communication platforms
9.4.2.1. Ensure coordinated communication on 
key events and products (L2)
n  Constant feed of news on EMCDDA 
activities and results
9.4.2.2. Organise events/product launches and 
support EMCDDA’s presence at conferences 
and technical meetings (as appropriate) (L2)
n  Awareness raising and positioning of 
EMCDDA’s work results and scientific 
expertise
n  Increased EMCDDA visibility in scientific 
activities
9.4.2.3. Organise European Drug Report launch 
(L2)
n  Report successfully launched across 
multiple communication platforms
9.4.2.4. Organise visits of external partners to 
EMCDDA (L2)
n  Dissemination of knowledge and experience, 
increased visibility of EMCDDA among 
academic, policy and professional audiences 
9.4.2.5. Examine feasibility of European drugs 
conference (to be organised in 2015, depending 
on resources) (L3)
n  Clear concept and milestones available
9.4.2.6. Continue to develop EMCDDA social 
media presence (Twitter, Facebook, etc.) and 
audiovisual service (L2)
n  Increased visibility for EMCDDA activities 
and products across social media and 
audiovisual channels
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Priority interventions Planned activities Expected outputs/results
9.4.3. Continue to build sound contacts and 
relations with journalists and provide media-
friendly information with clearly defined 
messages 
9.4.3.1. Revise media relations policy document 
and action points (L2)
n  Action points for 2014 and 15 prepared and 
2014 action points implemented 
9.4.3.2. Further develop contacts and relations 
with journalists and provide media-friendly 
information (L2)
n  Interviews set up, catalogue of journalist 
groups further developed
n  High-quality press products in accessible 
formats, including video footage
9.4.3.3. Assess impact through monitoring and 
press reviews (L2)
n  Clear view of return on investment from 
media activities through detailed press 
reviews and analyses
9.4.3.4. Organise training and tools for EMCDDA 
staff and Reitox network (L3)
n  Training organised, staff provided with 
improved communication skills and Reitox 
network with relevant tools
9.4.4. Public information service 9.4.4.1. Operate enquiry-answering service, 
produce website FAQs and other information 
(L2)
n  Efficient public information desk operates in 
line with guidelines set by the European 
Ombudsman
9.4.5. Library and documentation services 9.4.5.1. Provide reliable and efficient 
information, library and documentation services 
supporting the research needs of the scientific 
staff (L2)
n  Information bulletins published at regular 
intervals; ad hoc alerts distributed on an 
individual basis; literature searching; 
reference database construction and 
maintenance; management of library 
services
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achievement of the agency´s annual work programme, 
expected to reach 100 % for the activities listed as priority 
Level 1, 80 % for the Level 2 activities and 50 % for the Level 3 
activities.
Improving performance measurement will be the main 
objective in the area of strategic planning, monitoring and 
reporting in 2014. A top priority in the EMCDDA’s 2013–15 
strategy and work programme, the development of the 
performance measurement system started in 2013 based on a 
gradual implementation plan adopted internally and endorsed 
by the EMCDDA Management Board. Building on progress 
achieved in 2013 in developing indicators for the support 
areas, in 2014 the definition of performance indicators will be 
completed for all areas of work. Furthermore, the main features 
of the IT tool necessary to support the implementation of the 
system will be conceptualised and tested.
Another important area of work is the preparation of 
documents related to the strategic planning cycle. This is an 
ongoing activity, carried out every year, the main outputs of 
which are the General Report of Activities (GRA) for the year 
N-1, the mid-year monitoring report for the year N and the 
annual work programme for the year N+1. However, in 2014 
some new developments will take place, either emerging from 
the internal strategic planning cycle (such as the preparation 
of the new triennial work programme 2016–18), or due to 
external factors (such as the new Framework Financial 
Regulation). The main consequence will involve adjusting the 
internal strategic planning cycle, with earlier launch of the 
main programming exercises and submission of the 
documents to the agency’s external stakeholders.
In the area of internal control system and risk management, an 
ongoing task will be the monitoring of the state of compliance 
with the EMCDDA internal control standards (ICS) for 
effective management and control, which will be documented 
in a regularly updated repository. This work will be combined 
with regular updates to the central risk register introduced in 
2010 and will support risk managers on areas requiring 
risk-mitigating measures and/or upgrades of the key controls 
set in place.
The thorough verification of financial transactions will 
continue, to ensure that they are carried out in accordance 
with the relevant regulatory requirements, including sound 
financial management. In addition, as before, the agency will 
ensure appropriate implementation of recommendations 
addressed by the Internal Audit Service (IAS) and the 
European Court of Auditors (ECA) to the EMCDDA in 
accordance with suitably designed action plans.
I  II.10. Governance, management and networks
I Overview
Work continues in 2014 to successfully implement the 
2013–15 strategy and work programme. This is, however, a 
particularly challenging year, as the EMCDDA faces for the 
first time since its creation in 1993 substantial budget cuts 
owing to a significant decrease in the EU subsidy allocated to 
the agency. This will have a severe impact on the EMCDDA’s 
operations, which will need to be mitigated through even 
stronger measures at governance and management levels.
The Management Board will play an important steering role in 
2014, in order to ensure that the EMCDDA achieves most of its 
strategic objectives despite the difficult financial perspective. 
As is customary, two meetings of the Management Board will 
be organised, in July and in December. Four meetings of the 
Executive Committee and four meetings of the Budget 
Committee will be held during the course of the year providing 
sound support for the important work of the Board.
The Scientific Committee is the guardian of the EMCDDA’s 
scientific excellence. The Committee’s involvement in the 
planning process, the regular feedback it provides to units and 
scientific staff, its input as peer reviewers and ongoing advice 
provided through the year are core for our quality of work. 
Following the selection procedure carried out in 2013, a new 
Scientific Committee will start work in 2014. All activities 
linked to the renewal will take place as decided by the 
Management Board and in accordance with the rules. Ongoing 
support will be provided so as to make the two regular 
meetings of this statutory body of the EMCDDA successful 
and efficient.
In the area of management, the focus will be on further 
improving the working structure, organisation and methods, to 
support efficient implementation of activities and deal with 
the significant reduction in the agency´s annual budget. 
Optimisation of internal processes will be further pursued, in 
order to ensure that the agency’s resources are used in the 
most efficient, effective and economical manner. To this end, 
following the internal assessment completed in 2013, a list of 
concrete measures will be implemented with a view to 
rationalising use of resources and improving organisational 
performance.
The success of these sound leadership and management 
practices will ultimately be measured through the degree of 
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The EMCDDA attains good performance in carrying out the tasks set out in its recast Regulation and achievement of its 
objectives through good governance and efficient management and leadership
Goal 2013–15
Specific objective 10.1: Ensure good governance to provide the strategic guidance and direction for the work of the EMCDDA
Priority interventions Planned activities Expected outputs/results
10.1.1. Implement strategic decision-making 
process at the level of the Management Board
10.1.1.1. Coordinate, prepare and organise 
follow-up of the meetings and decisions of the 
Management Board, of the Executive 
Committee and of the Budget Committee (L1)
n  Two Management Board meetings, four 
Executive Committee meetings and four 
Budget Committee meetings organised and 
members provided with all the necessary 
documents and support to perform their 
duties
n  2015 Work Programme, 2015 budget, 2016 
preliminary draft budget (PDB) and other 
statutory decisions adopted
10.1.2. Provision of support and guidance by 
the Scientific Committee, to further enhance 
the scientific quality of the EMCDDA’s work
10.1.2.1. Coordinate, prepare and organise the 
meetings of the Scientific Committee and 
follow-up on the conclusions and 
recommendations (L1)
n  New Scientific Committee in place and fully 
operational
n  Two Scientific Committee meetings 
organised and members provided with all 
the necessary documents and support to 
perform their duties
n  Selected outputs peer reviewed by the 
Scientific Committee
Specific objective 10.2: Ensure efficient management and leadership to support achievement of results and efficient use of 
resources
Priority interventions Planned activities Expected outputs/results
10.2.1. Implement sound management 
organisation and practices
10.2.1.1. Optimise internal processes to ensure 
that the agency’s resources are used in the 
most efficient, effective and economical 
manner (L1)
n  Further measures to rationalise use of 
resources and improve organisational 
performance 
10.2.1.2. Ensure compliance with the data 
protection rules applicable to EU bodies, 
Regulation (EC) 45/2001 (L1)
n  Data protection rules applicable to EU 
bodies (Regulation (EC) 45/2001) observed 
in all EMCDDA activities
n  DPO activities report prepared and 
disseminated internally
10.2.1.3. Perform top-level and middle-level 
managerial activities, organise regular Heads of 
unit (HoU) and Coordination group meetings 
and implement the decisions made (L2)
n  Heads of unit meetings organised and 
decisions implemented
n  Coordination group meetings organised, 
supporting the preparation of the HoU 
meetings
Specific objective 10.3: Improve and implement the agency’s strategic planning and programming cycle processes, to support 
timely delivery of results and sound decision-making concerning allocation of resources and actions to be taken to enhance 
performance
Priority interventions Planned activities Expected outputs/results
10.3.1. Design and put in place an integrated 
performance measurement system to allow 
EMCDDA to better track progress of its 
achievements and detect implementation 
challenges in a timely way
10.3.1.1. Finalise definition of performance 
indicators for all the main areas of work, in line 
with the goals and objectives of 2013–15 
strategy and WP (L1)
n  Performance indicators in place for all the 
main areas
10.3.1.2. Develop the IT tool to support the 
performance measurement system (L2)
n  IT tool conceptualised, main features 
defined and tested
10.3.2. Prepare the documents required by 
the strategic planning and programming cycle
10.3.2.1. Prepare the strategic planning and 
programming cycle documents (L1)
n  2013 General Report of Activities published 
online by 15 June
n  2015 annual work programme submitted to 
the Management Board for adoption
n  Preparation of the EMCDDA’s 2016–18 
strategy and work programme started: 
informal consultation of key stakeholders and 
partners for collection of inputs/ideas; internal 
strategic reflection; concept for the document
10.3.2.2. Prepare and conduct the internal 2014 
mid-year monitoring exercise (L2)
n  Mid-year monitoring report prepared and 
used to support internal decision-making 
and planning
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Specific objective 10.4: Ensure effective internal control and risk management system
Priority interventions Planned activities Expected outputs/results
10.4.1. Implement sound internal control 
system
10.4.1.1. Verify thoroughly the financial 
transactions, notably as regards legality and 
regularity of operations, ensuring that they are 
made in accordance with the relevant 
regulatory requirements, including sound 
financial management (L1)
n  Ex-ante verification of all financial operations 
and corrections made where necessary
n  Recording of exceptions, particularly in 
cases of breaches of financial rules
n  Advice on best practices, notably as regards 
cost-effectiveness of operations, provided to 
internal actors
10.4.1.2. Perform ongoing monitoring of the 
state of implementation of the 16 EMCDDA 
internal control standards (ICS) for effective 
management and control (L2)
n  Regular assessment of the quality of the 
EMCDDA internal control systems carried 
out and repository updated
10.4.1.3. Update the central and sector risk 
registers as required under ICS 6 (L2)
n  Identification and assessment of risks posed 
to EMCDDA activities and timely setting up 
of action plans to mitigate those risks 
10.4.1.4. Liaise effectively with the EMCDDA 
Internal Auditor (Internal Audit Service of the 
EC, IAS) with a view to taking stock of 
recommendations arising from audits in areas 
of strategic importance (L2)
n  Proper implementation of recommendations 
addressed by the IAS to the EMCDDA in 
accordance with suitably designed action 
plans, leading to improvements in the 
internal controls object of recommendations
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I Reitox network
I Overview
In 2010 and 2011 the EMCDDA launched a systemic review, 
both internally and in consultation with the Reitox focal points. 
This review addresses, among others, the national reporting 
system that is part of the Reitox Framework Agreement adopted 
by the EMCDDA Management Board in 2003. In 2013, this 
review process gained impetus influenced by two combined 
factors: the emergence of new reporting needs, for instance in 
the area of the supply indicators, and the growing pressure on 
budgetary resources at European and national level.
As a consequence, new options to adapt the reporting system 
to this challenging context have been developed, with view to 
a proposal being adopted by the end of 2013 by the EMCDDA, 
its Management Board and the Reitox focal points. The scope 
and importance of the decisions to be taken will have a direct 
impact on the activities in priority intervention 10.5.1. 
Therefore, the expected results presented at this stage are 
provisional, as they will depend on the nature and content of 
the final decision.
Reitox network coordination tasks will focus on four main 
priorities and challenges: (1) coordinating the implementation 
of the new national reporting package, both as a tool for data 
collection and as a product, and providing full support for the 
transition phase in 2014; (2) managing with the NFPs the 
possible negative consequences of the reduction of the 
budget of the Grant Agreement at national level; (3) adapting 
the Reitox development strategy to the new framework and 
further highlighting the added value of the work of NFPs at EU 
and national levels; and (4) further developing, in consultation 
with the Reitox NFPs, the initial reference model for 
accreditation of the NFPs, taking into account the redefinition 
of the role and obligations of the NFPs in the context of the 
revised grant agreement.
Specific objective 10.5: Ensure that the Reitox network is efficiently managed and structured to meet future needs and 
requirements
Priority interventions Planned activities Expected outputs/results
10.5.1. Agree the annual reporting package 
and necessary developments to the overall 
reporting framework
10.5.1.1. Organise the Reitox Heads of focal 
point meetings (L1)
n  3rd Reitox week and 50th Heads of focal 
points (HFPs) meeting organised (June)
n  51st Reitox HFP meeting organised 
(November)
n  Meeting documents, presentations and 
results available online
10.5.1.2. Present to and agree with the Reitox 
NFPs the guidelines for national reporting (L1)
n  New guidelines adopted at the Heads of 
focal points meeting in November 
10.5.1.3. Organise the systematic consultation 
of NFPs for draft guidelines and for the 
periodical revision of tools before adoption at 
the Reitox meeting of November (L2)
n  Reitox technical meeting organised in 
September/October for analysis and 
discussion of first draft documents and 
agreement on way forward to prepare 
adoption at the November Reitox meeting
10.5.1.4. Implement the decision on the revision 
of the national reporting system (L1)
n  Implementation plan adopted
n  Intermediary steps foreseen for 2014 
implemented according to schedule
n  New support for national reporting (phase 1) 
delivered by EMCDDA according to deadline 
agreed in November 2013
n  New national reporting package (phase 1) 
delivered by NFPs end of September and 
end of October
n  First draft template for new 2015 EMCDDA 
national reports 
10.5.2. Strengthen the Reitox network at 
national level as a high-quality provider of 
information 
10.5.2.1. Provide on-site institutional support, in 
line with recommendations formulated in the 
quality reports (L2)
n  Institutional visits to the countries organised, 
as needed, and based on available resources 
10.5.2.2. Further develop the Reitox 
development strategy (L2)
n  Follow-up on the Reitox focus groups 
initiative (see also 8.2.2.1.)
10.5.2.3. Support the NFPs in the further 
elaboration of a Reitox Accreditation System 
(L3)
n  Concept for self-assessment tool developed 
(for discussion at the November HFP 
meeting)
10.5.3. Develop an integrated approach to 
capacity development and to quality 
assurance 
10.5.3.1. Support organisation of national and 
regional Reitox Academies upon request and 
needs from the NFPs (L3)
n  National or regional Reitox Academies 
organised for EMCDDA Member States, 
upon request and availability of funds
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Priority interventions Planned activities Expected outputs/results
10.5.4. Strengthen the management and 
organisational processes and procedures
10.5.4.1. Support NFPs in the management and 
implementation of their yearly grant agreement 
(L1)
n  28 grant agreements signed and 
implemented
n  NFPs better trained in EU financial regulation 
and consequent grant implementation
n  2-3 on-site audit visits and training support 
(as needed and in line with available 
resources)
10.5.4.2. Implement further steps to ensure 
that the management information system 
(HERMES) developed for the technical 
cooperation activities and management of 
grants is fully operational (L2)
n  HERMES reports used to track the progress 
of implementation of the work programme
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transactions and to developing and improving processes and 
tools for activity-based budgeting, monitoring and reporting, 
along with the accounting of assets.
Concerning human resources management, the focus will be 
on aligning EMCDDA rules, policies and processes to the 
expected reform of the EU staff regulations, as well as on 
further digitalising some of the HR processes.
In the area of logistics and infrastructure management, 
ensuring a healthy and safe working environment will remain a 
priority. Another priority is to reduce as much as possible 
utility costs by optimising the use of space and functioning of 
existing facilities. Special attention will be given to the 
development of solutions for business continuity.
The EMCDDA will continue its active cooperation with other 
EU agencies on administrative matters. This will include, 
among others, the representation of the EU Agencies’ network 
in the EU interinstitutional administrative bodies where 
EMCDDA staff members have been formally appointed to 
represent all EU decentralised agencies.
I  II.11. Administration: supporting core business
I Overview
In line with the goals set for the 2013–15 programming period, 
enhancing efficiency, further developing sound management 
of available resources and providing service-oriented 
administrative support to the EMCDDA’s operations will 
continue to be the main priorities within the administration 
area in 2014, along with the application of best practice. To 
this end, further synergies with the European Maritime Safety 
Agency (EMSA) will be promoted and developed.
Budget, financial management and accounting activities will 
focus on aligning the EMCDDA rules and processes to the 
revised EU financial regulation and the necessary training of 
the concerned actors, pursuant to the entry into force of the 
revised Framework Financial Regulation for EU Agencies. 
Furthermore, attention will be given to developing an ICT-
based tool to improve effectiveness and efficiency of financial 
Support to operations
Ensure effective and efficient allocation and management of financial and human resources and assets, through further 
rationalising internal processes, while developing the quality of services and support provided
Goal 2013–15
I Financial and budget management, and accounting
Specific objective 11.1: Enhance effectiveness and efficiency in the execution of the budget and in the management and 
accounting of financial resources
Priority interventions Planned activities Expected outputs/results
11.1.1. Align the EMCDDA’s financial rules with 
the revised EU financial regulation and ensure 
their implementation
11.1.1.1. Implement the revised EMCDDA 
financial rules (L1) 
n  Revised financial rules and updated 
procedures, manuals and templates applied
n  Financial and contractual support officers 
trained to ensure correct implementation of 
the revised rules
n  Financial actors trained to ensure correct 
implementation of the revised rules
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Priority interventions Planned activities Expected outputs/results
11.1.2. Further improve effectiveness and 
efficiency of financial transactions (payment 
process) and procurement processes
11.1.2.1. Carry out procurement activities and 
implement measures to rationalise and optimise 
tendering processes (L1)
n  2014 annual procurement plan in place and 
successfully executed
11.1.2.2. Conduct annual assessment of 
EMCDDA’s financial and administrative 
implementation of the budget and work 
programme (L2)
n  Further measures to improve budget 
execution and use of work programme 
resources 
11.1.2.3. Implement digitalised tools and 
processes (based on available resources) (L3)
n  Electronic workflow procedures 
conceptualised
n  ICT-based tool for staff missions 
management developed and piloted 
11.1.3. Ensure effective and timely preparation 
and use of budget planning and management 
tools in line with EMCDDA priorities and 
constraints and in accordance with ABM/ABB 
principles
11.1.3.1. Prepare and submit for approval the 
budget-planning instruments in a timely manner 
(L1)
n  EMCDDA 2015 draft budget and 2016 
preliminary draft budget 
11.1.3.2. Facilitate effective implementation of 
the 2014 budget (L1)
n  High rate of budget execution (over 97 % in 
terms of commitment appropriations and 
over 93 % in payment appropriations)
11.1.3.3. Prepare forecast analyses on impact 
of policy and operational issues on the budget, 
to support decision-making at management 
level (L2)
n  Budgetary scenarios and progress reports 
submitted in appropriate format
11.1.3.4. Further develop activity-based 
budgeting approach (L2)
n  Financial resources assigned/allocated to 
the second level of the cost centres (based 
on defined methodology) 
11.1.4. Develop customised reporting on 
budget execution
11.1.4.1. Structure the existing ABAC and 
financial data warehouse (L2)
n  Improved reporting tool, with a more 
user-friendly orientation 
11.1.4.2. Prepare budgetary reports, including 
visualisation of main budgetary trends (L2)
n  Regular statistical reports and customised 
reports on budget execution 
11.1.5. Improve the accounting of EMCDDA 
assets, and further define the conditions and 
requirements for the function of accounting 
officer at the EMCDDA according to applicable 
financial rules
11.1.5.1. Improve ISILOG assets management 
and business objects (L2) 
n  Current ISILOG system improved; more 
specific and regular reports developed
I Human resources management
Specific objective 11.2: Maximise efficiency and effectiveness of HR management at the EMCDDA
Priority interventions Planned activities Expected outputs/results
11.2.1. Align EMCDDA HR processes and 
policies with the forthcoming reform of the EU 
staff regulations 
11.2.1.1. Revise HR processes and policies in 
line with the new rules (L1)
n  Revised rights and entitlements
n  Employment contracts of temporary agents 
(TA) amended and signed (as needed, in line 
with the EU staff regulations)
n  New recruitment templates in place
11.2.1.2. Organise information sessions to staff 
(L2)
n  Information sessions on the main aspects of 
the reform organised and staff appropriately 
informed of rights/entitlements and 
obligations 
11.2.2. Further digitalise HR management 
processes through the development of ICT 
tools to increase efficiency and effectiveness
11.2.2.1. Develop further ICT tools to support 
HR management (L2)
n  HR support application suite (see 12.1.1.6.) 
11.2.3. Follow-up the outcome of the 2012 
staff opinion survey
11.2.3.1. Implement action plan to follow-up the 
survey (L3)
n  Action plan defined for 2014 implemented 
11.2.4. Further develop EMCDDA working and 
production capacity by maximising training 
opportunities for EMCDDA staff 
11.2.4.1. Develop/update the training plan as 
required to match working priorities and needs, 
and the available resources (L2)
n  Training plan in line with EMCDDA working 
priorities
11.2.4.2. Organise further training activities to 
improve managerial capacity (L2)
n  Training/coaching sessions provided to 
middle managers
11.2.5. Implement recruitment processes, 
where necessary, in line with the EMCDDA 
establishment plan and within the adopted 
budget
11.2.5.1. Carry out the necessary procedures 
for the recruitment, establishment and 
departure of statutory staff (officials, temporary 
agents, contract agents) and non-statutory staff 
(trainees, seconded national experts, interim, 
etc.) as requested to fulfil the establishment 
plan and the organisational needs (L1)
n  Available positions are filled in accordance 
with the budget available and organisational 
needs
n  Necessary recruitment, establishment and 
departure procedures carried out in 
accordance with the requirements of the 
Staff Regulation 
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I Infrastructure and logistics
Specific objective 11.3: Ensure a healthy working environment and further reduce utility costs by optimising the use of the 
available facilities, equipment and infrastructure
Priority interventions Planned activities Expected outputs/results
11.3.1. Ensure safety at work, sound 
environmental management and security in 
the buildings, including reducing utility costs 
and promoting use of renewable energy
11.3.1.1. Review annual security risk 
assessment of the EMCDDA to identify and 
evaluate risks, foresee new developments and 
propose mitigation measures to reduce impact 
and likelihood (L1)
n  Business continuity plan (BCP) implemented
n  Share best practice by participating in 
Security symposium and BCP seminar
n  Risk assessment prepared
11.3.1.2. Develop, put in place and promote an 
Environmental management system within the 
agency (L2)
n  Environmental management system in place
n  Contribution to the Greening network 
meeting
11.3.1.3. Conduct training of staff and wardens 
on evacuation procedures (L2)
n  Evacuation exercise carried out successfully
11.3.1.4. Implement measures to rationalise 
cost for utilities and service contracts (L1)
n  Further reduction in utility costs 
11.3.2. Provide a suitable working environment 
and related services, and improve efficiency 
and effectiveness through promoting a 
customer-oriented approach
11.3.2.1. Implement appropriate management 
of the premises and further improve access to 
logistics services, to provide optimal working 
conditions for EMCDDA staff (L2)
n  Health and safety risks identified and 
addressed
n  Increased use of e-support tools for service 
requests through the Infrastructure and 
logistics intranet (in comparison to 2013)
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(EDND). Investments will be also made in order to support 
corporate and administrative projects. Priority will be given to 
the development of a management information system (MIS) 
to support the new performance measuring system (see also 
Main area 10). Different options are currently being explored, 
including building on an existing internal application 
(HERMES, the grants management system), and the most 
cost-efficient one will be chosen by the end of 2013. Another 
priority will be the human resources support application, to 
allow the management of the modifications required by the 
new EU staff regulation.
Stepwise execution of the ‘Business and information 
architecture management’ programme encompasses the 
planning of business/IT architecture development and its 
technical implementation. The changing global landscape of 
ICT architectures and the related security and privacy threats 
require specific effort to maintain a balanced state and 
achieve controlled change and developments, something that 
is of concern in 2014.
The third priority intervention, to implement a ‘Technical 
services management’ programme, refers to the ongoing 
service management programme. This comprises most of the 
effort and resources dedicated to business-as-usual services; 
therefore, the majority of resources are earmarked for this 
area. The technical implementation of the Business 
architecture, addressed here, will lead to the planned 
replacement of central server components, network 
equipment and the standard software infrastructure. Formal 
procedures to ensure service availability and to leverage the 
advantages associated with any modifications will be 
promoted. Developing the role of the ICT Steering Committee 
and implementing best practice are also part of this 
intervention. A special focus for 2014 are the actions following 
the recommendations of the risk assessment carried out by 
the Internal Audit Service (IAS) and managing the risks 
included in the ICT section of the EMCDDA risk register, in 
particular in the area of security, project management and 
governance.
I  II.12. Information and communication technology (ICT)
I Overview
ICT programmes and services are planned to support the 
agency’s core development objectives and to guarantee the 
smooth operation of all up and running services. They include 
IT support for day-to-day work processes, maintenance of 
enterprise applications, hosting of enterprise applications and 
management of the data centre.
Developing ICT governance is central to helping the agency 
implement its work programme and carry out its mission, 
especially taking into account the anticipated financial 
constraints on the one hand, and increasing customer 
expectations and rapid technological developments on the 
other.
The most important share of the ICT annual budget is needed 
to maintain the operational status of existing services; 
therefore investments in new projects, in terms of either 
human of financial resources, must be strictly aligned with the 
agency’s top priorities.
Consistent with the overall approach applied to the agency’s 
2014 work programming exercise, a thorough prioritisation of 
projects and investments planned for the ICT area has been 
conducted. As a result, three levels of priority, as endorsed by 
the EMCDDA’s ICT Steering Committee, have been included 
in this 2014 Work Programme. These levels are strictly aligned 
with the ones defined for the core business areas, and the 
other areas of work requiring ICT support.
In order to develop and maintain instruments for supporting 
core business, in 2014 top priority will be given to: developing 
and maintaining the infrastructure for the annual drugs data 
collection and analysis; the web presence review programme; 
and the development of the European database on new drugs 
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Support the agency in achieving its objectives by providing high-quality and efficient ICT services
Goal 2013–15
Specific objective 12.1: Develop and maintain ICT solutions and tools to support the EMCDDA’s work processes, while applying 
best practices and standards of ICT governance, planning and service management
Priority interventions Planned activities Expected outputs/results
12.1.1. Develop and maintain instruments for 
supporting business
12.1.1.1. Develop and maintain infrastructure 
for the annual drugs data collection and 
analysis, reflecting the evolution of the drugs 
data set and its protocols (L1)
n  Fonte online data collection system set up 
for annual run; application updates 
performed during the year, as required
n  Analytical drugs database updated for 2014; 
concept for drugs data warehouse phase II 
developed
12.1.1.2. Support web content management 
and visualisation platform development (L1)
n  Pilot installation and configuration, ready for 
content migration
n  Major information systems and websites 
migrated
n  Platform operational, replacing the existing 
one for EMCDDA public websites
12.1.1.3. Develop EDND (L1) n  Strategic concept, analysis and design of the 
new EDND developed
n  New software and web interface developed 
and first version ready for use:
–  data input functionality operational
–  end user access to the database 
accessible to external and internal users
12.1.1.4. Implementation of networking tools 
and extranets support (L2)
n  Reitox network forum or extranet review to 
include social networking functionalities; 
study and implementation (phase 1)
n  Study the generalisation of the concept to 
support other extranets and expert networks
12.1.1.5. Develop a management information 
system (MIS) to support the performance 
measurement system (see also 10.3.1.2.) or 
build on existing internal solutions (To be 
confirmed) (L2)
n  Management information system designed
n  Pilot implementation of the system
12.1.1.6. Further develop the human resources 
support applications suite (L2)
n  Application requirements document 
completed
n  Partial analysis and design aiming at better 
estimating the investment required 
conducted 
12.1.1.7. Develop BPP information system (L3) n  Conceptualisation of new information 
system and technical requirements 
documents completed
12.1.1.8. Provide support for business review of 
the ‘monitoring the Internet’ programme (L3)
n  Functional analysis conducted and 
requirements identified
n  Programme supporting instruments 
upgraded
12.1.1.9. Mission management support 
application (L3)
n  Analysis and design
n  Pilot implementation
12.1.1.10. Document management programme 
(L3)
n  Programme approved
n  Most urgent projects started (e.g. 
digitalisation of staff records, electronic 
workflow support, digital identity)
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Priority interventions Planned activities Expected outputs/results
12.1.2. Implement Business and information 
architecture management programme
12.1.2.1. Business architecture programme (L2) n  Business and information/data architecture 
baselines defined
12.1.2.2. Information, data and application 
development process (L2)
n  Data architecture reviewed in light of 
changes in data and web publications
n  Drugs data Extract Transfer Load (ETL) 
architecture reviewed to better support data 
analysis and dissemination of results
n  Public key infrastructure (PKI), requirements 
and implementation plan
n  Business continuity support further 
developed
12.1.2.3. Security-related actions (L2) n  Analysis of security and privacy concerns in 
current and future architecture options
n  Implementation and gradual adoption of 
strong authentication
12.1.3. Implement the technical services 
management programme
12.1.3.1. ICT services provision (L1) n  The service catalogue as the instrument to 
manage the delivery of ICT services 
established
n  The required level of availability and stability 
of the technical infrastructure supporting 
services delivery ensured
12.1.3.2. Implement ICT governance ensuring 
correct planning and management of ICT 
resources (L2)
n  Project portfolio concept developed, in 
coordination with the ICT Steering 
Committee
n  Project management principles further 
developed and applied, in line with the IAS 
recommendations
n  Investments to maintain the technical 
infrastructure operating at the correct level 
of functionality and quality, minimising risks
n  Continued and improved collaboration 
through institutional networks (e.g. ICTAC)
12.1.3.3. Streamline ICT acquisition processes, 
using framework contracts and similar tools 
(L2)
n  Procurement processes optimised through 
increased collaboration on specific subjects/
dossiers with institutional networks, other 
agencies and European institutions
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Risk factors identified for delivery of the 
2014 Work Programme
Likelihood of risk and respective impact on the 2014 Work Programme 
External risks with a direct link to specific fields of the annual work programme
1. Substantial change from 2014 onwards 
to the amounts granted by the EC to the 
EMCDDA (when compared to amounts 
granted over the last years).
The 2014 Work Programme is drawn up on the basis of the value of financing foreseen for the 
budgetary year. The latest information available indicates that the amount of the EC grant for 2014 
could be some EUR 756 000 lower than for 2013. It seems likely at this stage that the amount of 
revenue for 2014 will decrease some 5 % from 2013 values. Against this background, further 
savings in all budget titles need to be assessed, so that outputs and results under the 2014 Work 
Programme will not be significantly affected by renewed budget constraints.
2. Lack of sufficient funding for NFPs in the 
Member States, which might have a negative 
impact on their capacity to comply with 
reporting obligations towards the EMCDDA. 
This risk could be compounded by 
insufficient funding of information collection 
in Member States as a whole (see 5 below), 
which in itself would limit NFP capability in 
providing reliable information to the 
EMCDDA.
All core monitoring activities could be affected, notably the review of developments in drug use 
and responses in Europe. The high political visibility of the drug phenomenon renders unlikely 
sizeable and widespread cuts in NFP financing and acts as a mitigating risk factor. However, and as 
a consequence of the EMCDDA’s own budget constraints, a decrease of its grants to the NFP is 
probable. Against this background, a review of the current national reporting package is underway, 
the aim of which is to lighten the burden on NFP resources, thereby ensuring sustainability of their 
work and quality of the core information provided. In view of the agency’s budget constraints in the 
near and medium-term horizon, commissioning new tasks to NFP staff by the EMCDDA does not 
appear feasible.
3. Supplementary specific requests from 
EU institutions to provide technical support 
for the implementation of EC programmes 
and actions, in particular as regards 
implementation of the Council Decision on 
new psychoactive substances. 
An extensive number of core tasks in support of the EU institutions (contribution to the EU drugs 
strategy, implementation of the Council Decision on new psychoactive substances, support to the 
second progress report for implementing the Council recommendation of 18.6.2003, support to drug 
policy dialogue at the EU level by providing expertise and technical information to the European 
Parliament, the Council and the European Commission, amongst others) have been foreseen for 
2014.
Additional requests from EU institutions to provide technical support for implementing actions and 
programmes would require priorities to be reviewed (6) or supplementary resources to be 
identified. Concerning, in particular, the implementation of the Council Decision on new 
psychoactive substances, and in view of the high number of psychoactive substances appearing 
over a short time period, a significant risk exists that multiple risk assessment exercises will be 
required, which would pose an additional burden on the work programme and the resources 
available. 
4. Supplementary requests from Member 
States and third parties to provide expertise 
in specific domains.
The current level of requests can be accommodated in routine work, but a significant increase in 
demand for this type of expertise would need additional scientific resources dedicated to it and 
would need to be balanced against other priorities of the work programme (see footnote).
5. Reduction of the reporting capacity of 
Member States as a whole due to lack of 
and/or reduced availability of core data with 
an adequate quality level. 
Core activities should not in principle be severely affected. However, the quality of certain 
publications (for instance, Monographs and Insights series) could suffer should this risk 
materialise. Moreover, when compared with recent experience outputs could become less 
comprehensive regarding the issues covered. The likelihood of occurrence and the impact of this 
risk can be considered as medium, since it is more acute in Member States experiencing a less 
favourable economic situation.
Should this risk materialise, planning of publications would have to be adjusted in accordance with 
the quality of information and expertise available in the areas concerned; this would entail 
reallocation of planned publications to alternative products, where feasible. 
External events that might have an impact on the implementation of the annual work programme as a whole.
6. Natural catastrophes: earthquakes 
(leading to possible tsunamis) or floods
The location of the EMCDDA facilities, bordering the Tagus river, raises a potential risk of being 
affected by any of these natural catastrophes.
The likely consequences of a major earthquake are hardly predictable and appropriate measures 
would have to be taken in order to deal with the resulting damages. The EMCDDA is presently 
located in an area of seismic activity. The likelihood of a tsunami comparable to the one that 
destroyed downtown Lisbon 258 years ago can be considered as very low, since it is clearly a rare 
phenomenon. A landslide of the building caused by earthquakes, although not very likely, cannot be 
ruled out.
As regards Tagus flooding, some information available (notably a report issued by Unisys in 2008) 
suggests that the potential risk here is low. On the other hand, it is conceivable that a combination 
of heavy rain with Tagus high tides could cause flooding of the underground car park. Further 
mitigating measures to deal with this risk ought to be agreed with and taken by the Administration 
of the Port of Lisbon (APL), the entity that owns the Cais do Sodré building. A letter in this sense 
was sent to APL in November 2010, followed by a reminder in July 2012.
I  ANNEX I Potential risk factors
(6)  The process for reviewing priorities is as follows: identify projects/meetings/studies/recruitments that can be delayed, downsized or cancelled and reassign 
resources appropriately.
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Risk factors identified for delivery of the 
2014 Work Programme
Likelihood of risk and respective impact on the 2014 Work Programme 
6. Natural catastrophes: earthquakes 
(leading to possible tsunamis) or floods
Furthermore, a comprehensive insurance contract covering inter alia adverse effects from 
earthquakes, landslides and floods has been signed and would provide financial compensation 
should these events materialise.
7. 1. Terrorist attacks The new facilities, as they are more visible than before, could, at least in theory, attract the attention 
of terrorist groups. The likelihood of such an event is considered as low, mostly because Portugal 
has no serious recent background of this kind of attack. Moreover, if the target of such actions were 
to be the EU institutions or the like, there are far more visible and emblematic institutions in 
Europe, a fact that should decrease the potential risk faced by the EMCDDA in this respect.
The insurance policy for the EMCDDA building covers inter alia this risk.
7.2. Social upheaval events acts of 
vandalism
The deterioration of the social situation in the country, notably as regards higher unemployment 
levels, could lead to riots potentially affecting the agency’s activities, namely by rendering more 
difficult access of its stakeholders (notably, staff, service providers and visitors) to the Cais do 
Sodré facilities and/or by causing physical damage to the premises.
The risk of minor acts of vandalism should be kept in mind, as they have occurred in the past. 
Emergence of more serious acts in this regard is possible, in view of both the social situation of the 
country and some of the clientele of Cais do Sodré. The permanent presence of guards and the 
existence of a video surveillance system mitigate this risk.
The insurance policy for the EMCDDA building also covers these risks.
Internal risks
8.1. Information Technology (IT) 
governance risks, notably linked to:
a) suboptimal investment decisions in IT;
b)  certain weaknesses in the management 
of IT projects; and
c)  insufficient licensing and assets 
management procedures.
A vast number of mitigating measures to deal with these risks have been implemented, namely:
a) setting up of a register with a categorisation of ICT investments; elaboration of a detailed report 
on ICT activities for 2010 and 2011 and 2012; setting up of a project catalogue for ICT; creation of 
an ICT investments Steering Committee; implementation of a project portfolio management 
process; adoption of the 2013–15 ICT strategic plan;
b) setting up of the ICT Advisory Committee; participation of the EMCDDA in interinstitutional 
Framework Contracts; adoption of a ‘turn-key’ approach to projects; definition and implementation 
of a project management methodology for ICT-managed projects;
c) use of suitable supporting tools to manage desktop computer applications and configurations.
A wide range of additional measures and actions is expected to further reduce existing risk levels 
to tolerable levels by mid-2014: a) to continue improving documentation of procedures and 
appropriate guidelines leading to sound decisions on IT investments; b) to foster implementation 
(on a pilot phase) of ICT projects in accordance with the new project management framework 
adopted in December 2012; c) to enhance planning and control of license and assets utilisation; to 
set up the ICT services catalogue allowing stakeholders’ needs for IT services to be better 
addressed.
8.2. Information Technology (IT) technical 
risks, notably linked to:
a)  software configuration management 
problems resulting from not properly 
planned installations of software;
b)  inconsistent application of patching 
procedures, compounded by insufficient 
documentation of interventions and 
systems updates;
c)  difficulties in ensuring business 
continuity and swift recovery in cases of 
incidents or disasters, due to both 
governance related and technical risks; 
and
d)  security violations, due to some lack of 
adequate procedures in the IT area.
Most relevant mitigating measures have already been implemented, such as: a) the setting up of an 
automatic monitoring system to deal with installed configurations; configuration audit exercises; 
implementation of technical tools addressing management of software configuration issues; 
conception of a ‘documentation tree’ as the basis for a future documentation set covering risk 
management, security and governance in IT; b) ‘ad hoc’ testing of potential consequences 
emerging from patching procedural weaknesses and systematic registration of interventions 
performed; setting up of a Definitive Software Library (DSL), indicating software versions in use 
and patches installed; c) definition of standards for a Business continuity plan (BCP) of the 
EMCDDA as a whole (thus also covering IT); hosting of the agency’s portal in degraded mode at an 
alternate site; use of a Framework Contract for the backup consolidation project supporting 
business continuity; procurement of specialised assistance services in cases of disaster; 
documentation of key technical dependencies in ICT; and d) installation of network management 
software combined with an update of the software version of Firewalls; introduction of modules for 
intrusion detection and prevention; increased protection against malware and virus threats.
Furthermore, a comprehensive set of additional measures has been foreseen in order to further 
reduce present risk levels: a) establishment of standard documentation on the EMCDDA ICT 
technical infrastructure and procedures to follow in operations; b) definition of specific guidelines 
for patching in servers; c) finalisation of the work started in implementing the Service Continuity 
and Disaster Recovery Plans; improvement of the existing documentation on dependencies 
amongst the components of the EMCDDA ICT infrastructure; further development of Santa 
Apolónia as the service continuity support site; accomplishment of a fully-fledged BCP; and d) to 
contract and carry out telecom security-related services, as well as external audits on sensitive 
areas of EMCDDA core business (for example, public web sites and the Fonte data collection 
application). 
9. Unexpected departure of key members 
of staff
Given the highly specialised and technical nature of much of the agency’s work, finding suitable 
replacements can be a time-consuming task. Furthermore, redeployment (notably in certain 
scientific areas) could prove to be unfeasible as it would require the existence of a pool of staff 
members with very comprehensive skills and expertise in the areas concerned. 
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a)  Reduced activities in support of partners and for non-core 
tasks;
b)  Delay or postponement of necessary developmental work, 
support and capacity-building activities;
c)  Reduction in capacity for analytical work and transversal 
products;
d)  Reduction in the scope and/or quality of planned outputs.
Except for major catastrophes (notably tsunamis), should any 
of the above scenarios occur, a detailed assessment of their 
impact both in budgetary and operational terms would have to 
be conducted. The implications of this assessment would then 
need to be considered in terms of the overall priorities of the 
work programme.
In case of major catastrophes, further measures would of 
course be needed.
The EMCDDA has used and will further strengthen its internal 
capacity to prevent, manage and minimise the impact of the 
abovementioned risks. Further to the mitigating measures 
described above, it has consistently improved the planning, 
monitoring, assessment and execution of its work programme 
and budget (activity planning and monitoring of work 
programmes have been assigned to the Director’s Office since 
2010). Moreover, close monitoring of the state of play of the 
EMCDDA 16 minimum ‘Internal Control Standards for 
effective management’ has been executed in the framework of 
the risk management exercise carried out at the agency, 
leading to a detailed repository on the respective state of 
implementation, to be regularly reviewed and updated.
I Risk management
The worst case scenario would be linked to a major 
earthquake leading to a tsunami. As stated above, an 
emergency/salvage plan to address the resulting damages 
would be needed. Even so, disruption of the EMCDDA 
activities would probably ensue, the respective duration being 
dependent on the severity of the catastrophe and of the 
promptness of the aid received from public and/or private 
sources.
It is to be noted that a very comprehensive insurance contract 
covering inter alia adverse effects arising from earthquakes, 
landslides, floods and terrorist attacks has been in force since 
2010 and would provide the necessary financial 
compensation should such events materialise. The 
responsibility for further measures aimed at mitigating the risk 
of floods at the building belong to its owner, the APL, as 
stipulated under the leasing contract.
Regarding specifically the IT area linked risks, which have 
been the subject of particularly close scrutiny, the main 
consequences would be related to business continuity. As 
regards governance, comprehensive mitigating measures 
taken over the last years have decreased risks, notably as 
regards soundness of investment decisions and management 
of assets and IT projects. Further action has been planned in 
this regard, which, combined with projects and programmes 
already being implemented, should bring residual risks to 
nearly tolerable levels in 2014.
Apart from the situations mentioned in the paragraphs above, 
the main consequences that could arise from materialisation 
of the risks identified would sequentially be:
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I  ANNEX II Estimated budget allocation for the implementation of the 2014 EMCDDA Work Programme
The amounts indicated in the table below are based on the 
parameters of the 2014 budget as they can be anticipated per 
16 September 2013. The budgetary procedures are still 
ongoing — both for the EMCDDA and the EU general budget. 
Therefore the budgetary figures at that moment and the 
distribution per main activities should be considered as 
broadly indicative.
According to the latest information available and subject to 
endorsement by the EMCDDA Management Board, the 2014 
budget will rely on the following revenues:
•   EUR 14 794 000 to be provided by the EU subsidy to the 
EMCDDA;
•   EUR 389 963 to be provided by Norway for its participation 
in the EMCDDA.
Furthermore, the 2014 budget enters as assigned 
appropriations a financing of EUR 200 000 from the IPA 
programme for the execution in 2014 of a project for technical 
assistance aimed at preparing IPA Beneficiaries for their 
participation in the EMCDDA (so called IPA 4 project – 3rd 
year of execution).
The tables below present the estimated allocation of the 2014 
budget appropriations for the implementation of the 2014 
Work Programme:
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A. Monitoring and reporting on the drugs problem in Europe (vertical operations)
WP objectives and activities
Main actors for 
implementation/ 
cost objects
Allocated human resources (fte/year: full time equivalent per year)
Allocated budget resources –  
Non assigned appropriations (EUR)
Officials
Temporary 
agents
Contract 
agents
Seconded 
national 
experts
Total HR
For direct cost  
of operations (1)
For indirect cost  
of operations (2)
Total budget 
Data collection, analysis and quality 
assurance
EPI + RTX 0.5 2.5 3 0 6 347 720.70 793 012.73 1 140 733.43
Monitoring and understanding drug use and 
problems: key indicators and epidemiology
EPI 0.5 5 1 0 6.5 208 788.75 534 313.96 743 102.70
Monitoring demand reduction responses 
applied to drug-related problems
IBS 1.7 4.7 0.7 0 7.1 99 148.99 336 767.81 435 916.80
Monitoring drug supply and supply reduction 
interventions
SAT 0 2.75 0.5 1 4.25 104 497.24 360 382.53 464 879.77
Monitoring new trends and developments 
and assessing the risks of new substances
SAT 0 3.25 1.5 0 4.75 104 497.24 411 831.87 516 329.11
Improving Europe’s capacity to monitor and 
evaluate policies
POL 0 3 1 0 4 208 788.81 555 697.52 764 486.33
Scientific coordination, research and content 
support
SDI + IBS + POL 1 4.5 0 0 5.5 123 072.16 433 395.28 556 467.44
Total 3.7 25.7 7.7 1 38.1 1 196 513.90 3 425 401.69 4 621 915.59
B. Cooperation and collaboration with key partners (transversal operations)
Objectives and activities
Main actors for 
implementation/ 
cost objects
Allocated human resources (fte/year)
Allocated budget resources –  
Non assigned appropriations (EUR)
Officials
Temporary 
agents
Contract 
agents
Seconded 
national 
experts
Total HR
For direct cost  
of operations (1)
For indirect cost  
of operations (2)
Total budget
Cooperation and collaboration with key 
partners
DIR + SDI + RTX 0.7 3.9 0 0 4.6 113 280.73 341 116.70 454 397.43
Total 0.7 3.9 0 0 4.6 113 280.73 341 116.70 454 397.43
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C. Supporting the achievement of results (transversal operations)
Objectives and activities
Main actors for 
implementation/ 
cost objects
Allocated human resources (fte/year)
Allocated budget resources –  
Non assigned appropriations (EUR)
Officials
Temporary 
agents
Contract 
agents
Seconded 
national 
experts
Total HR
For direct cost  
of operations (1)
For indirect cost  
of operations (2)
Total budget
Communicating the EMCDDA’s findings to 
external audiences (including translation)
COM 1 8 2 0 11 404 853.88 1 475 955.19 1 880 809.07
Governance, management and networks 
(executive and corporate management + 
Governing bodies’ activities)
DIR + IBS 3.3 5.3 2.3 0 10.9 298 269.62 1 001 965.05 1 300 234.67
RTX + NFPs´ 
co-financed 
activities
0.3 3.1 0 0 3.4 91 867.04 2 807 417.53 2 899 284.57
Total 4.6 16.4 4.3 0 25.3 794 990.54 5 285 337.76 6 080 328.30
Grand Total for Operations (A+B+C) 9 46 12 1 68 2 104 785.17 9 051 856.16 11 156 641.32
D. Support to operations under A, B and C above (overheads)
Objectives and activities
Main actors for 
implementation/ 
cost objects
Allocated human resources (fte/year)
Allocated budget resources for direct cost of supporting 
activities to be distributed to operations (2) (see above) –  
Non assigned appropriations (EUR)Officials
Temporary 
agents
Contract 
agents
Seconded 
national 
experts
Total HR
Administration: supporting core business ADM (administration 
and resources/
assets 
management)
3 11 7.5 0 21.5 2 954 104.75
Information and communication technology ICT (equipment and 
services)
0 8 2.5 0 10.5 1 073 216.56
Total 3 19 10 0 32 15 183 962.64
E. Grand total for operations and support to operations
Objectives and activities
Main actors for 
implementation/ 
cost objects
Allocated human resources (fte/year)
Allocated budget resources for direct cost of supporting 
activities to be distributed to operations (2) (see above) –  
Non assigned appropriations (EUR)Officials
Temporary 
agents
Contract 
agents
Seconded 
national 
experts
Total HR
Total 12 65 22 1 100 15 183 962.64
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F. Special projects 
(Funded by supplementary appropriations from EU budget on top of the EU regular annual subsidy to the EMCDDA)
Objectives and activities
Main actors for 
implementation/ 
cost objects
Allocated human resources (fte/year)
Allocated budget resources –  
Assigned appropriations (EUR)Officials
Temporary 
agents
Contract 
agents
Seconded 
national 
experts
Total HR
Preparation of IPA Beneficiaries Countries 
for their participation in the EMCDDA  
(IPA 4 project – 3rd year)
RTX  0 0 2  0 2 200 000
(1) Appropriations for cost/expenditure for operational activities and staff directly involved in the implementation of the EMCDDA mission/task/WP.
(2)  Overheads, i.e. appropriations for cost/expenditure for activities, equipment, infrastructure and staff that indirectly aim at implementing the EMCDDA mission/task/WP, as their immediate aim is to support operational activities and staff. These 
overheads are distributed to operational activities in proportion of the human resources assigned for the implementation of these activities.
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Attaining good performance is one of the EMCDDA’s strategic 
goals for 2013–15. In order to measure the accomplishment of 
this goal, the agency has committed to improving its 
performance measurement system through developing, 
among others, key performance indicators for each main area 
of work.
In line with the approach endorsed by the Management Board, 
the process is being developed in two phases. In the first 
phase, KPIs have been defined for the following areas: Main 
area 10, Governance, management and networks; Main area 
11, Administration – supporting core business; and Main area 
12, Information and communication technology.
These KPIs were designed to measure the yearly achievement 
of the specific objectives set up in the 2013–15 work 
programme, based on annual targets which are expected to 
be accomplished by the end of 2014. When defining the 
targets, an analysis of the baseline data (valid for 2012, the 
last completed year) was carried out first. In very few cases, 
the establishment of targets was not possible at this stage. 
This was due to either the need to obtain baseline data for 
2013, when the 2012 data was not relevant for the exercise 
(KPI 10.1.4.), or to the need to complete the definition of 
internal service standards which will represent the basis for 
measuring the indicator (KPI 12.1.2.).
I  ANNEX III Key performance indicators (KPIs)
It is important to note that 2014 will be the first year of 
implementation of the KPIs. This will therefore be a test year, 
when the methodologies for measuring the indicators will be 
further developed/improved and consolidated. Revisions of 
the methods of calculation and of the value of the targets are 
hence to be expected, as a natural development of the 
process.
In order to support the measurement of the KPIs, a detailed 
monitoring and evaluation (M&E) plan has been developed for 
internal use. For each indicator, the M&E plan includes 
information on the method of calculation, baseline, target, 
type of indicator, frequency of monitoring, reference 
documents and/or data sources, as well as responsibilities.
The process of developing KPIs will continue with the 
remaining areas, for which performance indicators will be 
defined for the 2015 work programme. This will allow more 
time to be dedicated to these areas using the lessons learned 
from the first phase. The system will be fully operational by the 
end of 2015, and its results will support the preparation of the 
end-term monitoring report of the 2013–15 work programme.
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I Main area 10: Governance, management and networks
Specific objective 10.1. Ensure good governance to provide strategic guidance and direction for the work of the EMCDDA
Key performance indicators Targets 2014
KPI 10.1.1. Effectiveness of the Management Board in performing its tasks, as 
stipulated by the EMCDDA’s founding Regulation (recast) and the applicable rules 
and procedures
All (100 %) issues addressed and decisions made as 
required by the EMCDDA’s founding Regulation (recast) 
and the applicable rules and procedures
KPI 10.1.2. Effectiveness of the Director in providing support to the Management 
Board (MB) for performing its tasks
a) 100 % of the supporting documents uploaded on the 
Management Board extranet at least two weeks before the 
MB meetings (except for documents related to events 
occurring within this timeframe)
b) Draft minutes of the MB meetings sent to the Chair 
within a maximum of eight weeks from the close of the 
meetings
KPI 10.1.3. Compliance with procedures to identify and deal with conflicts of interest 
for the members of the Management Board and of the Scientific Committee
Procedure to identify and deal with conflicts of interest 
defined and in place
KPI 10.1.4. Provision of scientific input/advice (in the form of peer review, formal 
opinions, input to protocols, projects, products, etc.) by the Scientific Committee, 
measured as percentage of requests met out of the total number of requests for 
input/advice sent by the Director and/or the Management Board 
To be defined by the end of 2013 
KPI 10.1.5. Effectiveness of the Director in providing support to the Scientific 
Committee (SC) in performing its tasks
a) 100 % of the supporting documents uploaded on the 
Scientific Committee extranet at least two weeks before 
the SC meetings (except for documents related to events 
occurring within this timeframe) 
b) Draft minutes of the SC meetings sent to the Chair 
within maximum two weeks from the close of the meetings
KPI 10.1.6. Degree of implementation of the follow-up action plan to the 3rd external 
evaluation of the EMCDDA, adopted by the Management Board in July 2012
100 %
Specific objective 10.2. Ensure efficient management and leadership to support achievement of results and efficient use of 
resources
Key performance indicators Targets 2014
KPI 10.2.1. Degree of implementation of the 2014 Work Programme 100 % of the expected outputs/results listed as level 1 
priority (L1), 80 % of the expected outputs/results listed as 
level 2 priority (L2) and 50 % of the expected outputs/
results listed as level 3 priority (L3) fully achieved
Specific objective 10.3. Improve and implement the agency’s strategic planning and programming cycle processes, to support 
timely delivery of results and sound decision-making concerning allocation of resources and actions to be taken to enhance 
performance
Key performance indicators Targets 2014
KPI 10.3.1. Degree of implementation of the performance measurement system a)  Performance indicators defined for all main areas of 
work 
b)  Tool to support planning, performance monitoring and 
reporting conceptualised and tested
KPI 10.3.2. Timely delivery of the documents supporting the strategic planning and 
programming cycle (three-year work programme, annual work programme, General 
Report of Activities) (as required by the EMCDDA founding recast Regulation)
All documents delivered within deadline 
Specific objective 10.4. Ensure effective internal control and risk management system
Key performance indicators Targets 2014
KPI 10.4.1. Degree of implementation of internal audit recommendations 100 % of the internal audit recommendations (‘critical’, ‘very 
important’ and ‘important’) implemented within the 
deadline foreseen in the follow-up action plan 
KPI 10.4.2. Number of reservations in the General Report of Activities (Declaration of 
assurance by the EMCDDA Authorising Officer)
No reservation
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I Reitox network
Specific objective 10.5. Ensure that the Reitox network is efficiently managed and structured to meet future needs and 
requirements
Key performance indicators Targets 2014
KPI 10.5.1. Execution rate (commitments) of the grant agreements budget 95 % 
KPI 10.5.2. Timely processing of the payment requests 85 % of the balance payment requests submitted complete 
and on time are successfully checked and paid by 30 June 
of year N+1
KPI 10.5.3. Level of satisfaction with the Reitox training activities 90 % satisfaction rate (as measured by training evaluation 
surveys) 
I Main area 11: Administration – supporting core business
Specific objective 11.1. Enhance effectiveness and efficiency in the execution of the budget and in the management and 
accounting of financial resources
Key performance indicators Targets 2014
KPI 11.1.1. Budget execution rate — commitment appropriations (without assigned 
appropriations)
Minimum 97 % of the total commitment appropriations 
KPI 11.1.2. Budget execution rate — payment appropriations (without assigned 
appropriations)
Minimum 93 % of the total payment appropriations
Specific objective 11.2. Maximise efficiency and effectiveness of HR management at the EMCDDA
Key performance indicators Targets 2014
KPI 11.2.1. Occupation rate (implementation of the establishment plan) 94 % of the establishment plan posts (officials, temporary 
agents) filled at the end of the year (in line with resources)
KPI 11.2.2. Staff turnover Maximum 4 % of the staff leaving EMCDDA during the year, 
out of the total number of staff (officials, temporary agents, 
contract agents)
KPI 11.2.3. Average number of training days per staff member three days
KPI 11.2.4. Average time of recruitment processes Maximum four months from the expiry date of the vacancy 
notice to appointment decision
Specific objective 11.3. Ensure a healthy working environment and further reduce utility costs by optimising the use of the 
available facilities, equipment and infrastructure
Key performance indicators Targets 2014
KPI 11.3.1. Number of accidents at work place No accident
KPI 11.3.2. Efficiency in using available facilities, equipment and infrastructure Reduction by 4 % of the utility costs (as compared to 2013)
I Main area 12: Information and communication technology
Specific objective 12.1. Develop and maintain ICT solutions and tools to support the EMCDDA’s work, while applying best 
practices and standards of ICT governance, planning and service management
Key performance indicators Targets 2014
KPI 12.1.1. Project management and implementation accountability (compliance 
with the EMCDDA’s adopted ICT Project management standard)
100 % 
KPI 12.1.2. Availability of the IT systems To be defined, based on the relevant Service Level 
Agreement defined by the EMCDDA ICT service catalogue 
(under development) 
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Pursuant to the applicable financial regulation and in line with 
the recommendation formulated by the Internal Audit Service 
(IAS) in 2013, this annex should indicate the procurements for 
non-administrative activities envisaged for the implementation 
of the EMCDDA 2014 Work Programme and whose estimated 
value is equal or higher than EUR 60 000, to be covered by 
appropriations entered into Title 3 of the relevant EMCDDA 
budget.
No such procurements have been envisaged for the 
implementation of the 2014 Work Programme.
I  ANNEX IV List of procurements
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•   ITALY: Presidenza del Consiglio dei Ministri – Dipartimento 
Politiche Antidroga (Presidency of the Council of Ministers 
– Department for Antidrug Policies), Rome.
•   LATVIA: Slimību profilakses un kontroles centra (Centre for 
Disease Prevention and Control of Latvia), Riga.
•   LITHUANIA: Narkotikų, Tabako ir Alkoholio Kontrolés 
Departhamentas (Drug, Tobacco and Alcohol Control 
Department), Vilnius.
•   LUXEMBOURG: Centre de Recherche Public – Santé 
(CRP-Santé), Luxembourg.
•   MALTA: Ministry of Justice, Dialogue and The Family, 
Valletta.
•   NETHERLANDS: Stichting Trimbos Instituut, Utrecht.
•   POLAND: Krajowe Biuro Do Spraw Przeciwdziałania 
Narkomanii (National Bureau for Drugs Prevention), Warsaw.
•   PORTUGAL: Serviço de Intervenção nos Comportamentos 
Aditivos e nas Dependências (SICAD), Lisbon.
•   ROMANIA: Agenţia Natională Antidrog (National Anti-drug 
Agency), Bucharest.
•   SLOVAKIA: Ministerstvo zdravotníctva Slovenskej republiky 
(Ministry of Health of the Slovak Republic), Bratislava.
•   SLOVENIA: Inštitut za Varovanje Zdravja Republike Slovenije 
(Institute of Public Health of the Republic of Slovenia), 
Ljubljana.
•   SPAIN: Delegación del Gobierno para el Plan Nacional sobre 
Drogas (Government Delegation for the National Plan on 
Drugs), Madrid.
•   SWEDEN: Statens Folkhälsoinstitut (National Institute of 
Public Health), Östersund.
•   UNITED KINGDOM: Department of Health, London.
Full contact details are available under the following link: 
www.emcdda.europa.eu/about/partners/reitox-network
•   AUSTRIA: Gesundheit Österreich GmbH (Austrian Health 
Institute), Vienna.
•   BELGIUM: Wetenschappelijk Instituut Volksgezondheid / 
Institut Scientifique de Santé Publique (Scientific Institute 
of Public Health) – Patrimoine (IPH-Patrimoine), Brussels.
•   BULGARIA: National Centre for Addictions (NCA BG), Sofia.
•   CROATIA: Vlada Republike Hrvatske – Ured za suzbijanje 
zlouporabe droga (Government of the Republic of Croatia 
– Office for Combating Narcotic Drugs Abuse), Zagreb.
•   CYPRUS: Εθνικο Κεντρο Τεκμηριωσησ Και Πληροφορησησ 
Για Τα Ναρκωτικα (Cyprus National Monitoring Centre for 
Drugs and Drug Addiction – EKTEPN), Nicosia.
•   CZECH REPUBLIC: Úřad vlády České republiky (Secretariat 
of the National Drug Commission – Office of the 
Government of the Czech Republic), Prague.
•   DENMARK: Danish Health and Medicines Authority, 
Copenhagen.
•   ESTONIA: Tervise Arengu Instituut (National Institute for 
Health Development - NIHD), Tallinn.
•   FINLAND: Terveyden Ja Hyvinvoinnin Laitos (National 
Institute for Health and Welfare - THL), Helsinki.
•   FRANCE: Observatoire Français des Drogues et des 
Toxicomanies (French Monitoring Centre for Drugs and Drug 
Addiction), Saint-Denis.
•   GERMANY: Institut für Therapieforschung (Institute for 
Therapy Research), Munich.
•   GREECE: Εθνικό Κέντρο Τεκμηρίωσης και Πληροφόρησης 
για τα Ναρκωτικά - ΕΚΤΕΠΝ (University Mental Health 
Research Institute), Athens.
•   HUNGARY: Országos Epidemiológiai Központ (National 
Centre for Epidemiology), Budapest.
•   IRELAND: Health Research Board (HRB) – Drugs Misuse 
Research Division, Dublin.
I  ANNEX V List of the beneficiaries of Reitox grants (national focal points)
56 / 58
The current grant agreement template is available under the 
following link: www.emcdda.europa.eu/about/partners/
reitox-network
I  ANNEX VI Template of the 2014 Reitox grant agreement
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I List of abbreviations and acronyms
ABB activity-based budgeting
ABM activity-based management
BCP Business continuity plan
CADAP The Central Asia Drug Action Programme
CEPOL European Police College
CICAD Inter-American Drug Abuse Control Commission
CoE / PG Council of Europe / Pompidou Group
COPOLAD Cooperation Programme between Latin America and the European Union on Drugs Policies
COSI Standing Committee on Internal Security of the European Union
CUP cross-unit project
DRD drug-related deaths
DRID drug-related infectious diseases
EC European Commission
ECDC European Centre for Disease Prevention and Control
EDND European database on new drugs
ELDD European legal database on drugs
EMA European Medicines Agency
EMDAS European Master in Drug and Alcohol Studies
EMS environmental management system
ENFSI European Network of Forensic Science Institutes
ENP European Neighbourhood Policy
ERANID European Research Area Network on Illicit Drugs
ESPAD European School Survey Project on Alcohol and other Drugs
EU European Union
EUFAS European Federation of Addiction Societies
EUSPR European Society for Prevention Research
EWS Early-warning system
GPS general population survey
HDG Horizontal Drugs Group 
HR human resources
IAS Internal Audit Service
ISAJE International Society of Addiction Journal Editors
IPA Instrument for Pre-Accession Assistance
ITN initial training network
JHA Justice and Home Affairs group, European Commission
KI key indicator
NFP national focal point
NPS new psychoactive substance
OAP Operational Action Plan
PCC potential candidate countries
PDU problem drug use
PhV Pharmacovigilance
TDI treatment demand indicator
UNAIDS Joint United Nations Programme on HIV/AIDS
UNODC United Nations Office on Drugs and Crime
WCO World Customs Organization
WHO World Health Organization
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